


A2



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 467 207 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

13.10.2004 Bulletin 2004/42

(51) Int Cl.7: **G01N 33/50, G01N 33/15,**

C07K 16/18, A61K 45/00,

A61K 48/00

(21) Application number: 03701036.0

(22) Date of filing: 09.01.2003

(86) International application number:

PCT/JP2003/000111

(87) International publication number:

WO 2003/060516 (24.07.2003 Gazette 2003/30)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SI SK TR

Designated Extension States:

AL LT LV MK RO

• MATSUO, Takanori

Ikeda-shi, Osaka 563-0026 (JP)

• TSUGE, Hiroko

Nishinomiya-shi, Hyogo 663-8106 (JP)

(30) Priority: 10.01.2002 JP 2002003769

(71) Applicant: Takeda Chemical Industries, Ltd.
Osaka-shi, Osaka 541-0045 (JP)

(74) Representative:

Rickard, Timothy Mark Adrian et al

Takeda Euro IP Department,

11-12 Charles II Street

London SW1Y 4QU (GB)

(72) Inventors:

• NODA, Masakuni

Takarazuka-shi, Hyogo 665-0861 (JP)

(54) SCREENING METHOD

(57) The present invention provides a screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid

sequence as that represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof.

EP 1 467 207 A1

Description

Technical Field

- 5 [0001] The present invention relates to a method for screening a prophylactic and therapeutic product for renal diseases and the like.

Background Art

- 10 [0002] As a protein comprising the amino acid sequence represented by SEQ ID NO: 1 is known Early Growth Response-1 (herein, abbreviated as Egr-1).
 [0003] Egr-1 is activated by ischemia and is a transcription factor that induces the expression of an important regulator for inflammation, coagulation and vascular permeability (Nature Medicine, vol. 6, No. 12, p.1355).
 [0004] So far, no reports on methods of screening a prophylactic and therapeutic product for a disease associated
 15 with Egr-1, using Egr-1 have been found.
 [0005] In addition, presently, as therapeutic products for renal diseases are used an angiotensin converting enzyme inhibitor and the like, but the inhibitor has an effect on renal circulation kinetics, thereby being incapable of using for renal function highly impaired patients.
 [0006] There is required a prophylactic and therapeutic product for a renal disease and the like, which have excellent
 20 effects and no adverse reactions, and a method for being able to screen such a prophylactic and therapeutic product.

Disclosure of the Invention

- 25 [0007] The present inventors, as a result of earnest studies to solve the above-described problem, have for the first time found out that the expression of renal Egr-1 in a renal disease model animal is remarkably increased, and further for the first time that suppression of the expression of renal Egr-1 in a renal disease model animal can produce a therapeutic effect on a renal disease. The present inventors have further carried out studies based on findings thereof, thus leading to the completion of the present invention.

[0008] In other words, the present invention relates to:

- 30 1) A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof;
 2) A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts
 35 thereof comprising the amino acid sequence represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof;
 3) The screening method according to 1), wherein the protein has the amino acid sequence represented by SEQ ID NO: 2;
 4) The screening method according to 1), wherein the disease is a renal disease;
 40 5) The screening method according to 4), wherein the renal disease is an Egr-1 depending renal disease;
 6) The screening method according to 4), wherein the renal disease is diabetic nephropathy;
 7) The screening method according to 1), which is characterized by comparing production of a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO:
 45 1 in the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 and the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of a test compound;
 8) The screening method according to 1), which is characterized by comparing an activity of a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO:
 50 1 in the presence of and in the absence of a test compound;
 9) The screening method according to 8), wherein the activity is a binding activity to the polynucleotide, to which the protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 are capable of binding;
 10) The screening method according to 8), wherein the activity is an expression-controlling activity of a gene under
 55 the control of transcriptional control by a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1;
 11) The screening method according to 1), which is characterized by measuring and comparing production of a protein or salts thereof comprising the same or substantially the same amino acid sequences as that represented

by SEQ ID NO: 1, and a binding activity to the polynucleotide, to which the protein or salts thereof is capable of binding, using a polynucleotide and an antibody against the protein or salts thereof in the case where a cell is cultivated that has the capability of producing the protein or salts thereof and the case where the cell is cultivated in the presence of a test compound;

12) A compound or salts thereof obtained by the screening method according to 1);

13) A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a compound or salts thereof obtained by the screening method according to 1);

14) A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using a polynucleotide comprising a base sequence or a partial sequence thereof encoding a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1;

15) A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using a polynucleotide comprising a base sequence or a partial sequence thereof encoding a protein or salts thereof comprising the amino acid sequence as that represented by SEQ ID NO: 1;

16) The screening method according to 14), wherein the polynucleotide comprises a base sequence or a partial sequence thereof represented by SEQ ID NO: 3 or SEQ ID NO: 4;

17) The screening method according to 14), wherein the disease is a renal disease;

18) The screening method according to 17), wherein the renal disease is an Egr-1 depending renal disease;

19) The screening method according to 17), wherein the renal disease is diabetic nephropathy;

20) The screening method according to 14), which is characterized by comparing the level of RNA encoding a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 and the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of a test compound;

21) A compound or salts thereof obtained by the screening method according to 14);

22) A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a compound or salts thereof obtained by the screening method according to 14);

23) An antibody against a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1;

24) A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises the antibody according to 23);

25) A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a polynucleotide having a complementary base sequence to the base sequence encoding a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, or its partial sequence;

26) A diagnostic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises the antibody according to 23);

27) A diagnostic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a polynucleotide having the base sequence or its partial sequence encoding a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1;

28) A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by comprising a polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6;

29) The prophylactic and therapeutic product according to 28), wherein the disease is a renal disease;

30) The prophylactic and therapeutic product according to 29), wherein the renal disease is an Egr-1 depending renal disease;

31) The prophylactic and therapeutic product according to 29), wherein the renal disease is diabetic nephropathy;

32) A prophylactic and therapeutic product for diabetic nephropathy comprising a suppressor of Egr-1;

33) The prophylactic and therapeutic product according to 32), wherein the suppressor of Egr-1 is a suppressor

of renal Egr-1;

34) A method for the prophylaxis and treatment of diabetic nephropathy in a mammal, which is characterized by administering a suppressor of Egr-1 to the mammal;

35) The method according to 34), wherein the suppressor of Egr-1 is a suppressor of renal Egr-1;

5 36) Use of a suppressor of Egr-1 for the manufacture of a prophylactic and therapeutic product for diabetic nephropathy;

37) Use according to 36), wherein the suppressor of Egr-1 is a suppressor of renal Egr-1; and the like.

Best Mode for Carrying Out the Invention

10

[0009] In the present invention, a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 (hereinafter, may be abbreviated as a protein of the present invention) may originate in cells (e.g., a liver cell, a retina cell, a nerve cell, a glial cell, a β cell of pancreas, a bone marrow cell, a mesangial cell, a Langerhans' cell, an epidermic cell, an epithelial cell, a goblet cell, an endothelial cell, a smooth muscle cell, a fibroblast, a fibrocyte, a myocyte, a fat cell, immune cells (e.g., macrophage, a T cell, a B cell, a natural killer cell, a mast cell, neutrophil, basophil, eosinophil, monocyte), megakaryocyte, a synovial cell, a chondrocyte, a bone cell, an osteoblast, an osteoclast, a mammary gland cell, a hepatocyte or an interstitial cell, or corresponding precursor cells thereof, a stem cell, a cancer cell, etc.), or any tissues where such cells are present, e.g., brain or any regions of the brain (for example, olfactory bulb, amygdaloid nucleus, basal ganglia, hippocampus, thalamus, hypothalamus, cerebral cortex, medulla oblongata, cerebellum), spinal cord, hypophysis, stomach, pancreas, kidney, liver, gonad, thyroid, gall-bladder, bone marrow, adrenal gland, skin, muscle, lung, gastrointestinal tract (e.g., large intestine and small intestine), blood vessel, heart, thymus, spleen, submandibular gland, peripheral blood, prostate, testis, ovary, placenta, uterus, bone, joint, skeletal muscle, etc. of warm-blooded animals (e.g., human, a mouse, a rat, a rabbit, a sheep, swine, bovine, a horse, a bird, a cat, a dog, a monkey, a chimpanzee, etc.). The protein may also be derived from a synthetic protein.

25

[0010] The amino acid sequence that comprises substantially the same amino acid sequence as that represented by SEQ ID NO: 1 includes an amino acid sequence having at least about 50% homology, preferably at least about 60% homology, more preferably at least about 70% homology, much more preferably at least about 80% homology, and most preferably at least about 90% homology, to the amino acid sequence represented by SEQ ID NO: 1.

30

[0011] Preferably, as the protein comprising substantially the same amino acid sequence as that represented by SEQ ID NO: 1, for example, mentioned is a protein comprising substantially the same amino acid sequence as represented by the aforementioned SEQ ID NO: 1 and having substantially the same activity as that of a protein comprising the amino acid sequence represented by SEQ ID NO: 1, or the like.

35

[0012] Substantially the same activity includes, for example, a transcription controlling activity of a fibrosis relating gene, a cell cycle relating gene and a thrombus relating gene, and the like. Substantially the same stands for properties thereof being equivalent in properties (for example, in physiology or in pharmacology). Accordingly, preferably, the transcription controlling activity is equivalent (e.g., about 0.01 to 100 times, preferably about 0.1 to 10 times, more preferably 0.5 to 2 times), but quantity factors such as the extent of activities, the molecular weights of proteins and the like may be different.

40

[0013] The fibrosis relating genes include, for example, platelet-derived growth factor-A chain (PDGF-A chain), platelet-derived growth factor-B chain (PDGF-B chain), basic fibroblast growth factor (bFGF), fibroblast growth factor 2 (FGF2), tumor growth factor- β 1 (TGF- β 1), tumor necrosis factor- α (TNF- α), intercellular adhesion molecule 1 (ICAM-1), vascular endothelial cell growth factor (VEGF), PDGF β receptor (PDGF β R), insulin-like growth factor-1 receptor (IGF-1 R), fibronectin, α 2 (1) collagen, and the like. The cell cycle relating genes include, for example, p53 and the like. The thrombus relating genes include, for example, plasminogen activator inhibitor-1 (PAI-1), a tissue factor (TF), metalloproteinase, and the like.

45

[0014] The measurement of the transcription controlling activity can be carried out by publicly known method, for example, the method of Shi-Fang Yan et al. (Proc. Natl. Acad. Sci. USA Vol. 95, pp 8298-8303, 1998), or an analogous method thereto.

50

[0015] In addition, the protein of the present invention includes, for example, proteins such as muteins, wherein [1] one or two or more amino acids (preferably, from about 1 to about 30, preferably from about 1 to about 10, more preferably several (from 1 to 5) amino acids) of the amino acid sequence represented by SEQ ID NO: 1 are deleted, [2] one or two or more amino acids (preferably, from about 1 to about 30, preferably from about 1 to about 10, more preferably several (from 1 to 5) amino acids) of the amino acid sequence represented by SEQ ID NO: 1 are added, [3] one or two or more amino acid (preferably, from about 1 to about 30, preferably from about 1 to about 10, more preferably several (from 1 to 5) amino acids) of the amino acid sequence represented by SEQ ID NO: 1 are inserted, [4] one or two or more amino acids (preferably, from about 1 to about 30, preferably from about 1 to about 10, more preferably several (from 1 to 5) amino acids) of the amino acid sequence represented by SEQ ID NO: 1 are substituted with other

55

amino acids, and [5] the an amino acid sequence in combinations with the above.

[0016] For the insertion, deletion or substitution of an amino acid sequence described above, the position of the insertion, deletion or substitution is not particularly limited.

[0017] The protein of the present invention preferably comprises a protein having the amino acid sequence represented by SEQ ID NO: 2, and thus Egr-1.

[0018] With proteins herein, the left end is the N terminal (the amino terminal) and the right end is the C terminal (the carboxyl terminal) in accordance with the conventional peptide marking. For the protein of the present invention as well as a protein comprising the amino acid sequence represented by SEQ ID NO: 1, the C terminal may be any of a carboxyl group (-COOH), a carboxylate (-COO⁻), an amide (-CONH₂), and an ester (-COOR).

[0019] Here, R of the esters for use include, for example, C₁₋₆ alkyl groups such as methyl, ethyl, n-propyl, isopropyl, and n-butyl; C₃₋₈ cycloalkyl groups such as cyclopentyl and cyclohexyl; C₆₋₁₂ aryl groups such as phenyl and α -naphthyl; C₇₋₁₄ aralkyl groups such as phenyl-C₁₋₂ alkyl groups such as benzyl and phenethyl; and α -naphthyl-C₁₋₂ alkyl groups such as α -naphthylmethyl; a pivaloyloxymethyl group; and the like.

[0020] When the protein of the present has a carboxyl group (or a carboxylate) in addition to the C terminal, a group in which the carboxyl group is subjected to amidation or esterification is also included in the protein of the present invention. In this case, the esters for use include, for example, an ester of the above-mentioned C terminal, and the like.

[0021] Furthermore, the protein of the present invention also includes proteins in which the amino groups (e.g., a methionine residue) of N terminals are protected by protecting groups (e.g.: C₁₋₆ acyl groups including C₁₋₆ alkanoyl groups such as a formyl group and an acetyl group; and the like), proteins made by subjecting glutamine residues of the N terminal, which are produced by cleavage in vivo, to pyroglutamine oxidation, proteins produced by protecting substituents (for example, -OH, -SH, an amino group, an imidazole group, an indole group, a guadinino group, and the like) on the side chains of intramolecular amino acids by suitable protecting groups (e.g.: C₁₋₆ acyl groups including C₁₋₆ alkanoyl groups such as a formyl group and an acetyl group; and the like), conjugated proteins such as a glyco-protein produced by bonding a sugar chain to a protein, and the like.

[0022] As salts of the protein of the present invention, salts with physiologically acceptable acids (e.g., an inorganic acid and an organic acid), bases (e.g., alkaline metal salts) and the like are used, particularly physiologically acceptable acid addition salts are preferable. These salts for use include, for example, salts with inorganic acids (for example, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid), salts with organic acids (for example, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, succinic acid, tartaric acid, citric acid, malic acid, oxalic acid, benzoic acid, methanesulfonic acid, benzenesulfonic acid), and the like.

[0023] The protein or salts thereof of the present invention can be produced by publicly known protein purification methods from the above-mentioned cells or tissues of a warm-blooded animal. Specifically, the protein or salts thereof of the present invention can be produced by a method that involves homogenizing tissues or cells of a warm-blooded animal, and then separating and purifying the soluble fraction by chromatography such as a reverse chromatography or an ion exchange chromatography.

[0024] The protein or salts thereof of the present invention can also be produced in accordance with publicly known peptide synthesis processes.

[0025] The peptide synthesis processes may be any of; for example, a solid phase synthesis process and a liquid phase synthesis process. A target protein can be produced by a process that includes condensing a partial peptide or an amino acid capable of forming the protein of the present invention with a remaining portion, and subsequently removing a protecting group when the resultant product has the protecting group.

[0026] Here, the condensation and the removal of the protecting group are conducted on the basis of publicly known methods, for example, including the methods indicated in [1] to [5] below:

- [1] M. Bodanszky and M.A. Ondetti: Peptide Synthesis, Interscience Publishers, New York (1966);
- [2] Schroeder and Luebke: The Peptide, Academic Press, New York (1965);
- [3] Nobuo Izumiya, et al.: Peptide Gosei-no-Kiso to Jikken (Basics and experiments of peptide synthesis), published by Maruzen Co. (1975);
- [4] Haruaki Yajima and Shunpei Sakakibara: Seikagaku Jikken Koza (Biochemical Experiment) 1, Tanpakushitsu no Kagaku (Chemistry of Proteins) IV, 205 (1977); and
- [5] Haruaki Yajima, ed.: Zoku Iyakuho no Kaihatsu (A sequel to Development of Pharmaceuticals), Vol. 14, Peptide Synthesis, published by Hirokawa Shoten.

[0027] A protein thus obtained can be purified and isolated by publicly known purification methods. Here, the purification methods include, for example, a solvent extraction, a column chromatography, a liquid chromatography, recrystallization, combinations thereof, and the like.

[0028] When a protein obtained by the above-mentioned methods is a free form, the free form can be converted into a suitable salt by publicly known methods or analogous methods thereto. Conversely, if a protein is obtained in the

form of a salt, the salt can be converted into a free form or another salt by publicly known methods or analogous methods thereto.

[0029] The protein or salts thereof of the present invention is normally synthesized using commercially available protein synthesizing resins. These resins include, for example, a chloromethyl resin, a hydroxymethyl resin, a benzhydrylamine resin, an aminomethyl resin, a 4-benzyloxybenzyl alcohol resin, a 4-methylbenzhydrylamine resin, a PAM resin, a 4-hydroxymethylmethylphenylacetamidomethyl resin, a polyacrylamide resin, a 4-(2',4'-dimethoxyphenyl)-hydroxymethyl)phenoxy resin, a 4-(2',4'-dimethoxyphenyl)-Fmoc aminoethyl)phenoxy resin, and the like.

[0030] Using such a resin, amino acids in which an α -amino group and a side chain functional group are appropriately protected are condensed on the resin according to the sequence of a desired protein based on publicly known condensing methods. Simultaneously with cleaving the protein from the resin at the end of reaction, various protecting groups are removed, and further the resultant protein is subjected to an intramolecular disulfide bond-forming reaction in a highly diluted solution to yield a desired protein.

[0031] Condensation of the above-mentioned protected amino acids can utilize a variety of activating agents capable of being used for protein synthesis, but particularly carbodiimides are preferable. The carbodiimides for use include DCC, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, and the like.

[0032] Condensation of protected amino acids is performed by, for example, directly adding the protected amino acids along with an activating agent and a racemization suppressing additive (e.g., HOBt and HOObt) to the resin, or by adding the resin, after the protected amino acids are activated in advance to yield symmetric acid anhydrides or HOBt esters or HOObt esters, to the resin.

[0033] Solvents used for activation of protected amino acids and condensation of protected amino acids with a resin are, as required, selected from solvents that are known to be capable of being used for protein condensation reactions. Examples of the solvents for use include acid amides such as N,N-dimethylformamide, N,N-dimethylacetamide, and N-methylpyrrolidone; halogenated hydrocarbons such as methylene chloride and chloroform; alcohols such as trifluoroethanol; sulfoxides such as dimethylsulfoxide; amines such as pyridine; ethers such as dioxane and tetrahydrofuran; nitriles such as acetonitrile and propionitrile; esters such as methyl acetate and ethyl acetate; suitable mixtures thereof; and the like.

[0034] The reaction temperature is, as necessary, selected from the range that is known to be used in protein condensation reactions, and normally is, as appropriate, from the range of about -20°C to about 50°C. An activated amino acid derivative is normally used from 1.5 to 4 times in excess. When the condensation is insufficient as the result of the test using a ninhydrin reaction, sufficient condensation can be carried out by repeating the condensation reaction without elimination of the protecting group. If the condensation is insufficient even though the condensation reaction is repeated, sufficient condensation can be conducted by acetylating unreacted amino acids using acetic anhydride or acetylimidazole.

[0035] A protecting method and a protecting group of a functional group that should not be involved in the reaction of raw materials, a method of removing the protecting group, a method of activating a functional group involved in the reaction, and the like can be, as required, selected from well-known groups or well-known means.

[0036] The protecting groups of an amino group of the amino acid starting materials include, for example, Z, Boc, t-pentyloxycarbonyl, isobomylloxycarbonyl, 4-methoxybenzyloxycarbonyl, C1-Z, Br-Z, adamantyloxycarbonyl, trifluoroacetyl, phthaloyl, formyl, 2-nitrophenylsulfonyl, diphenylphosphinothioyl, Fmoc, and the like.

[0037] A carboxyl group of the amino acid starting materials can be protected, for example, by alkyl esterification (e.g., linear, branched or cyclic alkyl esterification with methyl, ethyl, propyl, butyl, t-butyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 2-adamantyl, and the like), aralkyl esterification (e.g., esterification with benzyl, 4-nitrobenzyl, 4-methoxybenzyl, 4-chlorobenzyl, benzhydryl), phenacyl esterification, benzyloxycarbonyl hydrazidation, t-butoxycarbonyl hydrazidation, trityl hydrazidation, or the like.

[0038] The hydroxyl group of serine can be protected by, for example, esterification or etherification. Suitable groups for esterification include, for example, lower (C_{1-6}) alkanoyl groups such as an acetyl group, aroyl groups such as a benzoyl group, and groups derived from carbonic acid such as benzyloxycarbonyl group, ethoxycarbonyl group, and the like. In addition, appropriate groups for etherification include, for example, a benzyl group, a tetrahydropyranyl group, a t-butyl group, and the like.

[0039] The protecting groups of the phenolic hydroxyl group of tyrosine include, for example, Bzl, Cl_2 -Bzl, 2-nitrobenzyl, Br-Z, t-butyl, and the like.

[0040] The protecting groups of the imidazole of histidine include, for example, Tos, 4-methoxy-2,3,6-trimethylbenzenesulfonyl, DNP, benzyloxymethyl, Bum, Boc, Trt, Fmoc, and the like.

[0041] The methods of removing (eliminating) a protecting group include, for example, catalytic reduction under a flow of hydrogen gas in the presence of a catalyst such as Pd-black or Pd-carbon; acid treatment by means of anhydrous hydrogen fluoride, methanesulfonic acid, trifluoromethane-sulfonic acid, trifluoroacetic acid, or a mixture solution thereof; base treatment by means of diisopropylethylamine, triethylamine, piperidine or piperazine; and reduction with sodium in liquid ammonia. The elimination reaction by the above-described acid treatment is generally carried out at a

temperature of from about -20°C to about 40°C. The acid treatment is efficiently conducted by adding a cation scavenger such as anisole, phenol, thioanisole, m-cresol, p-cresol, dimethylsulfide, 1,4-butanedithiol or 1,2-ethanedithiol. Also, a 2,4-dinitrophenyl group used as a protecting group of the imidazole of histidine is removed by thiophenol treatment. A formyl group used as a protecting group of the indole of tryptophan is removed by acid treatment in the presence of 1,2-ethanedithiol, 1,4-butanedithiol, or the like, as well as by alkali treatment of a dilute sodium hydroxide solution, dilute ammonia, or the like.

[0042] Those obtained by activation of carboxyl groups in the amino acid starting materials for use include, for example, a corresponding acid anhydride, an azide, an activated ester (an ester with an alcohol (e.g., pentachlorophenol, 2,4,5-trichlorophenol, 2,4-dinitrophenol, cyanomethyl alcohol, p-nitrophenol, HONB, N-hydroxysuccinimide, N-hydroxyphthalimide, or HOBt)). Those obtained by activation of amino groups in the amino acid starting materials for use include, for example, a corresponding phosphoric amide.

[0043] An amide of a protein can be produced, in accordance with publicly known methods, by amidation of the α -carboxyl group of the carboxy terminal amino acid of the protein.

[0044] An ester of a protein can be produced, for example, by condensing the α -carboxyl group of the carboxy terminal amino acid of the protein with a desired alcohol.

[0045] Furthermore, the protein or salts thereof of the present invention can also be prepared by cultivating a transformant comprising the DNA encoding the protein of the present invention, and subsequently separating and purifying the protein or salts thereof from the resultant culture.

[0046] DNA encoding the protein of the present invention includes genomic DNA, a genomic DNA library, cDNA derived from the cells and tissues described above, cDNA libraries derived from the cells and tissues described above and synthetic DNA. A vector to be used for a library may be any of a bacteriophage, a plasmid, a cosmid, a phagemid, and the like. In addition, the DNA can also be amplified by reverse transcriptase polymerase chain reaction (hereinafter abbreviated as RT-PCR) using the total RNA or mRNA fractions prepared from the cells and tissues mentioned above.

[0047] DNA encoding the protein of the present invention includes, for example, DNA comprising a base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4, and DNA which comprises a base sequence hybridizable to a base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4 under highly stringent conditions, and which encodes the above protein having substantially the same activity (e.g., a transcription controlling activity of a fibrosis relating gene, a cell cycle relating gene, or a thrombus relating gene, or the like) as that of a protein comprising the amino acid sequence represented by SEQ ID NO: 1.

[0048] DNA, for use, hybridizable to a base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4 under highly stringent conditions include, for example, DNA comprising a base sequence having at least about 50%, preferably at least about 60%, more preferably at least about 70%, more preferably at least about 80%, much more preferably at least about 90% and most preferably at least about 95% identity to the base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4, and the like.

[0049] Hybridization can be carried out by publicly known methods or analogous methods thereto, for example, in accordance with the method described in Molecular Cloning, 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989). Also, when a commercially available library is utilized, hybridization can be conducted according to the protocol described in the attached instructions. Preferably, hybridization can be carried out under highly stringent conditions.

[0050] The highly stringent conditions stand for, for example, those in a sodium concentration of about 19 to about 40 mM, preferably about 19 to about 20 mM at a temperature of about 50°C to about 70°C, preferably about 60°C to about 65°C. In particular, the cases where a sodium concentration is about 19 mM and where the temperature is about 65°C are preferable.

[0051] DNA encoding a protein comprising the amino acid sequence (preferably the amino acid sequence represented by SEQ ID NO: 2) represented by SEQ ID NO: 1 preferably includes DNA comprising the amino acid sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4, and the like.

[0052] DNA completely encoding the protein of the present invention can be cloned by amplification by means of a PCR method using a synthetic DNA primer having a part of the base sequence encoding the protein of the present invention, or hybridization of DNA inserted into an appropriate expression vector with a DNA fragment encoding a part or entire region of the protein of the present invention, or with a labeled, synthetic DNA fragment. Hybridization can be carried out, for example, in accordance with the method described in Molecular Cloning, 2nd, J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989 and the like. Also, when a commercially available library is employed, hybridization can be performed according to the protocol described in the attached instructions.

[0053] Use of publicly known kits such as Mutan™-super Express Km (Takara Shuzo Co., Ltd.), Mutan™-K (Takara Shuzo Co., Ltd.), and the like, can convert a base sequence of DNA in accordance with publicly known methods such as the ODA-LA PCR method, the Gapped duplex method or the Kunkel method, or analogous methods thereto.

[0054] DNA encoding a cloned protein can be used, depending on purposes, directly or, if desired, after digestion with a restriction enzyme or after addition of a linker thereto. The DNA has ATG as a translation initiation codon on the 5' terminal side, and may have TAA, TGA or TAG as a translation termination codon on the 3' terminal side. These

translation initiation and termination codons can be added by means of an appropriate synthetic DNA adapter.

[0055] The aforementioned expression vector can be produced, for example, by excising a target DNA fragment from DNA encoding the protein of the present invention, and linking the DNA fragment to the downstream of a promoter in an appropriate expression vector.

5 [0056] The expression vectors for use include a plasmid derived from *E. coli* (e.g., pBR322, pBR325, pUC12, or pUC13); a plasmid derived from *Bacillus subtilis* (e.g., pUB110, pTP5, or pC194); a plasmid derived from yeast (e.g., pSH19, or pSH15), a bacteriophage such as λ phage; animal viruses such as a retrovirus, a vaccinia virus, or a baculovirus; pA1-11, pXT1, pRc/CMV, pRc/RSV, pcDNA1/Neo, and the like.

[0057] The promoter may be any promoter suitable with a host to be used for gene expression.

10 [0058] For instance, when the host is an animal cell, the promoters for use include an SR α promoter, an SV40 promoter, an LTR promoter, a CMV (Cytomegalovirus) promoter, an HSV-TK promoter, and the like. Of these, a CMV promoter, an SR α promoter, and the like are preferable.

[0059] If the host is a bacterium of the genus *Escherichia*, the preferred promoters include a trp promoter, a lac promoter, a recA promoter, a λ P_L promoter, an lpp promoter, a T7 promoter, and the like.

15 [0060] In the case of using a bacterium of the genus *Bacillus* as the host, the preferred promoters include an SPO1 promoter, an SPO2 promoter and a penP promoter and the like.

[0061] When yeast is used as the host, the preferred promoters include a PHO5 promoter, a PGK promoter, a GAP promoter, ADH promoter, and the like.

20 [0062] Where the host is an insect cell, the preferred promoters include a polyhedrin promoter, a P10 promoter, and the like.

[0063] The expression vector, in addition to the above, can optionally utilize an expression vector that comprises an enhancer, a splicing signal, a polyA addition signal, a selection marker, an SV40 replication origin (hereinafter may be abbreviated as SV40ori), and the like. The selection markers include, for example, a dihydrofolate reductase (hereinafter may be abbreviated as dhfr) gene [methotrexate (MTX) resistance], an ampicillin resistant gene (hereinafter may be abbreviated as Amp^r), a neomycin resistant gene (hereinafter may be abbreviated as Neo^r, G418 resistance), and the like. In particular, when a dhfr gene defective Chinese hamster cell is used and when a dhfr gene is used as a selection marker, a target gene can also be selected by a thymidine free medium.

25 [0064] In addition, as required, a signal sequence that matches with a host is added to the N terminal of the protein of the present invention. When the host is a bacterium of the genus *Escherichia*, a PhoA signal sequence, an OmpA signal sequence, and the like are utilized. When the host is a bacterium of the genus *Bacillus*, an α -amylase signal sequence, a subtilisin signal sequence, and the like are used. When the host is yeast, an MF α signal sequence, a SUC2 signal sequence, and the like are used. When the host is an animal cell, an insulin signal sequence, an α -interferon signal sequence, an antibody molecule signal sequence, and the like are employed.

30 [0065] A transformant comprising DNA encoding the protein of the present invention can be prepared in accordance with publicly known methods by transforming the host using an expression vector comprising the DNA.

[0066] Here, the expression vectors include the above-mentioned expression vectors.

[0067] The hosts for use include, for example, a bacterium of the genus *Escherichia*, a bacterium of the genus *Bacillus*, yeast, an insect cell, an insect, an animal cell, and the like.

35 [0068] The bacteria of the genus *Escherichia*, which are used, include, for example, *Escherichia coli* K12 DH1 (Proc. Natl. Acad. Sci. U.S.A., 60, 160 (1968)), JM103 (Nucleic Acids Research, 9, 309 (1981)), JA221 (Journal of Molecular Biology, 120, 517 (1978)), HB101 (Journal of Molecular Biology, 41, 459 (1969)), C600 (Genetics, 39, 440 (1954)), etc.

[0069] The bacteria of the genus *Bacillus* for use include, for example, *Bacillus subtilis* M114 (Gene, 24, 255 (1983)), 207-21 (Journal of Biochemistry, 95, 87 (1984)), etc.

40 [0070] The yeast for use includes, for example, *Saccharomyces cerevisiae* AH22, AH22R, NA87-11A, DKD-5D, 20B-12, *Schizosaccharomyces pombe* NCYC1913, NCYC2036, *Pichia pastoris* KM71, and the like.

45 [0071] The insect cells for use include, for example, a cell in which the virus is AcNPV, a *Spodoptera frugiperda* cell (a Sf cell), a MG1 cell derived from the mid-intestine of *Trichoplusia ni*, a High Five™ cell derived from an egg of *Trichoplusia ni*, a cell derived from *Mamestra brassicae*, a cell derived from *Estigmene acrea*, and the like. With the virus BmNPV, a *Bombyx mori* N cell (a BmN cell), and the like are used as insect cells. The Sf cells for use include, 50 for example, a Sf9 cell (ATCC CRL1711), a Sf21 cell (both in Vaughn, J. L. et al., In Vivo, 13, 213-217 (1977), and the like.

[0072] The insects for use include, for example, a larva of *Bombyx mori* (Maeda, et al., Nature, 315, 592 (1985)), and the like.

55 [0073] The animal cells for use include, for example, a monkey cell COS-7, Vero, a Chinese hamster cell CHO (hereafter abbreviated as a CHO cell), a dhfr gene defective Chinese hamster cell CHO (hereafter abbreviated as a CHO(dhfr) cell), a mouse L cell, mouse AtT-20, a mouse myeloma cell, rat GH3, a human FL cell, and the like.

[0074] Transformation can be carried out according to the kinds of hosts in accordance with publicly known methods.

[0075] A bacterium of the genus *Escherichia* can be transformed, for example, in accordance with a method described in Proc. Natl. Acad. Sci. U.S.A., 69, 2110 (1972), Gene, 17, 107 (1982), etc.

[0076] A bacterium of the genus *Bacillus* can be transformed, for example, according to a method described in Molecular and General Genetics, 168, 111 (1979), etc.

[0077] Yeast can be transformed, for example, in accordance with a method described in Methods in Enzymology, 194, 182-187 (1991), Proc. Natl. Acad. Sci. U.S.A., 75, 1929 (1978), etc.

[0078] An insect cell and an insect can be transformed, for example, according to a method described in Bio/Technology, 6, 47-55 (1988), etc.

[0079] An animal cell can be transformed, for example, in accordance with a method described in Saibo Kogaku (Cell Engineering), extra issue 8, Shin Saibo Kogaku Jikken Protocol (New Cell Engineering Experimental Protocol), 263-267 (1995), published by Shujunsha, or Virology, 52, 456 (1973).

[0080] Cultivation of a transformant can be carried out according to the kind of hosts in accordance with publicly known methods.

[0081] For instance, when a transformant whose host is a bacterium of the genus *Escherichia* or the genus *Bacillus*, a medium for cultivation is preferably a liquid medium. Also, the medium preferably comprises a carbon source, a nitrogen source, an inorganic material, and the like, necessary for the growth of the transformant. Here, the carbon sources include, for example, glucose, dextrin, soluble starch, sucrose, and the like. The nitrogen sources include, for example, inorganic and organic materials such as an ammonium salt, a nitrate salt, corn steep liquor, peptone, casein, meal extract, soybean cake, potato extract, and the like. The inorganic materials include, for example, calcium chloride, sodium dihydrogenphosphate, magnesium chloride, and the like. In addition, to the medium may also be added yeast extract, vitamins, growth promoting factor, and the like. Preferably, the pH of the medium is from about 5 to about 8.

[0082] The media in the case where a transformant whose host is a bacterium of the genus *Escherichia* is cultivated preferably include, for example, a M9 medium supplemented with glucose and a Casamino acid (Miller, Journal of Experiments in Molecular Genetics, 431-433, Cold Spring Harbor Laboratory, New York, 1972). As required, in order to efficiently activate a promoter, a chemical such as β -indolylacrylic acid may also be added to the medium.

[0083] Cultivation of a transformant whose host is a bacterium of the genus *Escherichia* is normally carried out at about 15°C to about 43°C for about 3 to about 24 hours. As necessary, the culture may be aerated or agitated.

[0084] Cultivation of a transformant whose host is a bacterium of the genus *Bacillus* is normally carried out at about 30°C to about 40°C for about 6 to about 24 hours. As necessary, the culture may be aerated or agitated.

[0085] The media in the case where a transformant whose host is yeast is cultivated include, for example, a minimal medium of Burkholder (Bostian, K. L. et al., Proc. Natl. Acad. Sci. U.S.A., 77, 4505 (1980)), a SD medium comprising a 0.5% Casamino acid (Bitter, G. A. et al., Proc. Natl. Acad. Sci. U.S.A., 81, 5330 (1984)), etc. Preferably, the pH of the medium is from about 5 to about 8. Cultivation is normally conducted at about 20°C to about 35°C for about 24 to about 72 hours. As needed, the culture may be aerated or agitated.

[0086] The media for use in the case where a transformant whose host is an insect cell or an insect is cultivated include, for example, Grace's Insect Medium (Grace, T. C. C., Nature, 195, 788 (1962)) to which an additive such as immobilized 10% bovine serum is added, as appropriate, and the like. Preferably, the pH of the medium is from about 6.2 to about 6.4. Cultivation is normally carried out at about 27°C for about 3 to about 5 days. As needed, the culture may be aerated or agitated.

[0087] The media for use in the case where a transformant whose host is an animal cell is cultivated include, for example, a MEM medium containing about 5 to about 20% of a fetal bovine serum (Science, 122, 501 (1952)), a DMEM medium (Virology, Vol. 8, 396 (1959)), a RPMI 1640 medium (The Journal of the American Medical Association, 199, 519 (1967)), a 199 medium (Proceeding of the Society for the Biological Medicine, 73, 1 (1950)), etc. Preferably, the pH of the medium is from about 6 to about 8. Cultivation is normally carried out at about 30°C to about 40°C for about 15 to about 60 hours. As required, the culture may be aerated or agitated.

[0088] As discussed so far, the protein of the present invention can be produced in a cell, in a cell membrane, or outside a cell, of a transformant.

[0089] The protein of the present invention can be separated and purified from a culture obtained by cultivating the transformant in accordance with publicly known methods.

[0090] For example, when the protein of the present invention is extracted from a cultivated bacterium or cell, a method which involves suspending a bacterium or a cell collected from a culture by publicly known methods in an appropriate buffer, disrupting the bacterium or the cell by ultrasonication, lysozyme and/or freeze-thaw cycling, and then obtaining a crude extract by centrifugation, or filtration; or the like is used, as appropriate. The buffer may contain a protein modifier such as urea or guanidine hydrochloride, or a surfactant such as Triton X-100™, and the like. Additionally, extraction of the protein of the present invention from a nucleus fraction is conducted by a method that includes treating the precipitate obtained by the aforementioned centrifugation, or filtration with hypertonic solution or the like, and subsequently collecting the supernatant by centrifugation to thereby obtain a crude extract of the nucleus protein, or a similar method. When the protein is secreted in the culture, a method is used wherein the culture supernatant is collected from the culture by publicly known methods.

[0091] The culture supernatant or the protein contained in extract thus obtained can be separated and purified in

accordance with publicly known methods. Such methods for use include a method that utilizes solubility such as salting out, or solvent precipitation; a method that utilizes mainly difference in molecular weight such as dialysis, ultrafiltration, gel filtration, SDS-polyacrylamide gel electrophoresis, or the like; a method that utilizes difference in electric charge such as ion exchange chromatography, or the like; a method that utilizes specific affinity such as affinity chromatography, or the like; a method that utilizes difference in hydrophobicity such as reverse phase high performance liquid chromatography, or the like; a method that utilizes difference in isoelectric point such as isoelectrofocusing electrophoresis; and the like. These methods can be, as appropriate, used in combination as well.

[0092] When the protein thus obtained is in a free form, it can be converted into a salt by publicly known methods or analogous methods thereto; if the protein is obtained in the form of a salt, it can be converted into a free form or in the form of a different salt by publicly known methods or analogous methods thereto.

[0093] Moreover, the protein produced by the transformant can also arbitrarily be modified by the action of an appropriate protein-modifying enzyme, prior to or subsequent to the purification, or a polypeptide thereof can also be removed partially. The protein-modifying enzymes for use include, for example, trypsin, chymotrypsin, arginyl endopeptidase, protein kinase, glycosidase, and the like.

[0094] The presence of the thus produced protein of the present invention can be confirmed by an enzyme immunoassay using a specific antibody, the western blotting technique or the like.

[0095] The diseases associated with the protein of the present invention include diseases in which the amount of the protein of the present invention is increased or decreased when comparing with that of the normal time.

[0096] Here, "diseases in which the amount of the protein of the present invention is increased when comparing with that of the normal time" include, for example, renal diseases (e.g., diabetic nephropathy; chronic glomerulonephritis; IgA nephropathy; chronic rejection after kidney transplantation; renal carcinosarcoma; and peritoneal sclerosis accompanied with peritoneal dialysis); circulating system diseases (e.g., arterial sclerosis; myocardial infarction; a cardiac failure; myocardiopathy; re-hemadostenosis after PTCA and stent indwelling; chronic rejection after cardiac and blood vessel transplantation; and thrombosis); cerebral blood vessel disorders (e.g., cerebral infarction); lung diseases (e.g., pneumonic fibrosis, chronic obstructive pulmonary syndrome, lung cancer); liver diseases (e.g., liver cirrhosis, hepatitis, liver cancer); digestive tract diseases (e.g., colitis, gastric cancer, large intestine cancer); gonadal diseases (e.g., prostate cancer); collagen diseases (e.g., scleriosis, systemic erythematosus); rheumatic diseases (e.g., chronic arthral rheumatism); and bone diseases (e.g., osteoporosis); and the like.

[0097] The "diseases in which the amount of the protein of the present invention is decreased when comparing with that of the normal time" include, for example, digestive tract diseases (for example, gastric ulcer and duodenal ulcer); skin diseases (for example, a burn and a wound after surgery); and the like.

[0098] Diseases associated with the protein of the present invention preferably comprise "diseases in which the amount of the protein of the present invention is increased when comparing with that of the normal time."

[0099] In addition, diseases associated with the protein of the present invention are preferably Egr-1 depending diseases that develop depending on the amount of Egr-1 in the body.

[0100] Diseases associated with the protein of the present invention are preferably renal diseases, more preferably Egr-1 depending diseases. In particular, renal Egr-1 depending renal diseases are preferable.

[0101] The present invention relates to a screening method for a prophylactic and therapeutic substance for diseases associated with the protein of the present invention, which is characterized by using the protein.

[0102] The screening method of the present invention is carried out, for example, by 1) comparing the amount of production of the protein of the present invention in the case where a cell having the capability of producing the protein of the present invention is cultivated with that of production of the protein of the present invention in the case where a cell having the capability of producing the protein of the present invention is cultivated in the presence of a test compound; 2) comparing the activity of the protein of the present invention in the case where a cell having the capability of producing the protein of the present invention is cultivated with that of the protein of the present invention in the case where a cell having the capability of producing the protein of the present invention is cultivated in the presence of a test compound; 3) comparing the activity of the protein of the present invention in the presence of and in the absence of a test compound; and the like.

[0103] The cell having the capability of producing the protein of the present invention is not limited as long as it is a cell having the capability of producing the protein, but a cell is preferable wherein production of the protein (preferably Egr-1) of the present invention is derived depending on a variety of stimuli such as an oxidation stress and a proliferation factor (hereafter, may comprehensively be referred to as "Egr-1 expression deriving factor") treatment.

[0104] The cell having the capability of producing the protein of the present invention may also be the aforementioned "transformant comprising DNA encoding the protein of the present invention." Preferable examples of the cell having the capability of producing the protein of the present invention include, for example, a cell isolated from a kidney of a mammal (preferably, a human, a rat, a mouse, or the like). These cells may also be immortalized cells.

[0105] The cell having the capability of producing the protein of the present invention is cultivated as for the aforementioned transformant.

[0106] The test compounds include, for example, a peptide, a protein, a non-peptidic compound, a synthetic compound, a fermented product, a cell extract, a plant extract, an animal tissue extract, and the like.

[0107] The protein of the present invention can be quantitatively determined by publicly known methods, for example, methods using an antibody to the protein of the present invention such as western analysis and the ELISA method, or analogous methods thereto.

[0108] The antibody to the protein of the present invention may be any of monoclonal and polyclonal antibodies as long as it is an antibody that can recognize the protein of the present invention. Additionally, the antibody may be an antibody molecule itself, and F(ab')₂, Fab', or Fab fraction of the antibody molecule. Also, an antibody may be labeled as well.

[0109] The labeling agent used for labeling an antibody includes, for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance, and the like. The radioisotope for use include, for example, [¹²⁵I], [¹³¹I], [³H], [¹⁴C], and the like. The enzyme for use is preferably stable and high in specific activity, and includes, for example, β-galactosidase, β-glucosidase, alkaline phosphatase, peroxidase, malate dehydrogenase, and the like. The fluorescent substance for use includes, for example, fluorescamine, fluorescein isothiocyanate, and the like. The luminescent substance for use includes, for example, luminol, a luminol derivative, luciferin, lucigenin, and the like. Furthermore, the biotin-avidin system can also be used for binding an antibody or an antigen to the labeling agent.

[0110] When the protein of the present invention is quantified, a protein to be quantified may be any of proteins contained in a cell or secreted to the outside of a cell, or the total of both also.

[0111] In addition, where the protein of the present invention contained in a cell is quantified, it is preferably quantified after the cell is treated with a suitable immobilizing solution or a membrane permeation promoting agent. Moreover, after the cell is suspended in an appropriate buffer and destroyed with a supersonic wave or by freeze melt, the protein in the crashed solution can be determined as well. As required, after the protein in the crashed solution is separated and purified, the protein may also be quantified.

[0112] The activity of the protein of the present invention used in the screening method of the present invention include, for example, a transcription controlling activity and the like, and more specifically, for example, a "binding activity to the polynucleotide, to which the protein of the present invention is capable of binding", an "expression-controlling activity of a gene under the control of transcription control by the protein of the present invention", and the like.

[0113] The polynucleotide includes, for example, a polynucleotide comprising a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 described below (preferably, a polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6), and the like.

[0114] The above-mentioned binding activity can be measured by publicly known methods, e.g., the method of Shi-Fang Yan, et al. (Proc. Natl. Acad. Sci. U.S.A. 95, 8298-8303, 1998) or an analogous method thereto using electrophoretic mobility shift assay. Or, the activity can also be measured by immobilizing on a suitable solid phase (e.g., a microtiter plate, and the like) the above polynucleotide to which the protein of the present invention is capable of binding (e.g., contacting the biotin-labeled polynucleotide with a (strepto)avidin-immobilized solid phase; or the like), adding to the solid phase the protein (or a fraction comprising it) of the present invention and a labeled antibody to the protein of the present invention (or an antibody to the protein of the present invention and a secondary labeled antibody for the antibody) and reacting them, and then quantifying the protein of the present invention bonded to the solid phase in accordance with the methods such as an ELISA method and the like or analogous methods thereto. Here, when the protein of the present invention is provided by a culture obtained by cultivating a cell having the capability of producing the protein of the present invention, the amount of production of the protein of the present invention in the cell can be determined at the same time. In addition, a cell can be cultivated, as necessary, under the stimulus of an Egr-1 expression deriving factor.

[0115] The "gene under the control of transcription control by the protein of the present invention" includes a fibrosis relating gene, a cell cycle relating gene, and a thrombus relating gene, which were shown as the above-mentioned "substantially the same activity".

[0116] The expression-control activity of these genes can be measured in accordance with the method discussed in the EXAMPLES by preparing an appropriate primer from the DNA sequence encoding the gene, conducting RT-PCR, and then measuring the amount of transcription product of the gene. Additionally, the aforementioned expression-control activity can be measured according to publicly known methods, for example, the method of Shi-Fang Yan, et al. (Proc. Natl. Acad. Sci. U.S.A. 95, 8298-8303, 1998) or an analogous method thereto by means of the northern blotting method that uses a probe prepared by labeling a polynucleotide comprising the base sequence of DNA encoding the gene. Also, the aforementioned expression-control activity can also be measured in accordance with publicly known methods, for example, the method of Shi-Fang Yan, et al. (Proc. Natl. Acad. Sci. U.S.A. 95, 8298-8303, 1998) or an analogous method thereto that involves preparing a vector wherein a transcription control region comprising the base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 on the DNA encoding the "gene under the control of transcription control by the protein of the present invention" and a suitable reporter gene are linked, introducing the vector into an appropriate cell, and subsequently confirming the expression of the protein encoded by the reporter gene.

[0117] The above-described screening method makes it possible to screen a prophylactic and therapeutic substance for diseases associated with the protein of the present invention, and thus a compound regulating (promoting or inhibiting) the production of the protein of the present invention, or a compound regulating (promoting or inhibiting) the activity of the protein of the present invention.

5 [0118] For instance, a test compound that increases the amount of the protein of the present invention by about 20% or more, preferably by about 30% or more, and more preferably by about 50% or more, can be selected as a compound for promoting the production of the protein of the present invention; a test compound that decreases the amount of the protein of the present invention by about 20% or more, preferably by about 30% or more, and more preferably by about 50% or more, can be selected as a compound for inhibiting the production of the protein of the present invention.

10 [0119] For example, a test compound that increases the activity of the protein of the present invention by about 20% or more, preferably by about 30% or more, and more preferably by about 50% or more, can be selected as a compound for promoting the activity of the protein of the present invention; a test compound that decreases the activity of the protein of the present invention by about 20% or more, preferably by about 30% or more, and more preferably by about 50% or more, can be selected as a compound for inhibiting the activity of the protein of the present invention.

15 [0120] Furthermore, in the above-described screening method, in place of comparing the amount of production of the protein of the present invention in the presence of and in the absence of a test compound, when the quantification and comparison of the amount of the protein of a cell or another test organism derived from an animal that is possibly infected by a disease associated with the protein or salts thereof of the present invention and that of the protein of the present invention in a cell or another test organism of a normal control animal leads to the confirmation of an increase or decrease in the amount of the protein in the test organism, it is possible to diagnose the test organism being infected by a disease associated with the protein of the present invention, or the test organism being to be highly possibly infected by the disease.

20 [0121] Moreover, similarly, if the quantification and comparison of the activity of the protein of the present invention results in the confirmation of an increase or decrease in the activity of the protein in the test organism, it is possible to diagnose the test organism being infected by a disease associated with the protein of the present invention, or the test organism being to be highly possibly infected by the disease.

25 [0122] The prophylactic and therapeutic substance for diseases associated with the protein of the present invention, obtained by utilizing the screening method of the present invention, may be any of a peptide, a protein, a non-peptide compound, a synthetic compound, a fermented product, a cell extract, a plant extract, an animal tissue extract, plasma, and the like. These may form salts, and examples of the salts include similar salts to the salts of the protein of the present invention discussed above.

30 [0123] The prophylactic and therapeutic substance (compound) for diseases associated with the protein of the present invention, obtained by the screening method of the present invention, can be used as a prophylactic and therapeutic product for diseases associated with the protein of the present invention after processing into a pharmaceutical composition by admixing, as required, with a pharmacologically acceptable carrier.

35 [0124] Here, examples of the pharmacologically acceptable carrier include a variety of organic and inorganic carrier substances conventionally used as preparation materials, and these are formulated as excipients, lubricants, binders, and disintegrators, in solid preparations; as solvents, solubilizing agents, suspending agents, isotonicizing agents, buffering agents, and soothing agents, in liquid preparations, and the like. Also, as necessary, preparation additives such as antiseptics, antioxidants, coloring agents, sweeteners, and the like can be employed.

40 [0125] The excipients suitably include, for example, lactose, saccharose, D-mannitol, D-sorbitol, starch, gelatinized starch, dextrin, crystalline cellulose, low substituted hydroxypropyl cellulose, sodium carboxymethyl cellulose, gum arabic, dextrin, pullulan, light silicic acid anhydride, synthetic aluminum silicate, magnesium metasilicate aluminate, and the like.

45 [0126] Examples of the suitable lubricants include magnesium stearate, calcium stearate, talc, colloidal silica, and the like.

[0127] Examples of the suitable binders include gelatinized starch, sucrose, gelatin, gum arabic, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, crystalline cellulose, saccharose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrrolidone, and the like.

50 [0128] Examples of the suitable disintegrators include lactose, saccharose, starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium crosscarmellose, sodium carboxymethyl starch, light silicic acid anhydride, low substituted hydroxypropyl cellulose, and the like.

[0129] Examples of the suitable solvents include injection water, physiological saline, Ringer's solutions, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil, and the like.

55 [0130] Examples of the suitable solubilizing agents include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanol amine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate, and the like.

[0131] Examples of the suitable suspending agents include surfactants such as stearyl triethanol amine, sodium

lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glycerin monostearate; e.g., hydrophilic polymers such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose; Polysorbates, polyoxyethylene hardened castor oil, and the like.

[0132] Examples of the suitable isotonicizing agents include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, and the like.

[0133] Examples of the suitable buffering agents include buffers of a phosphate, an acetate, a carbonate, a citrate, and the like.

[0134] Examples of the suitable soothing agents include benzyl alcohol and the like.

[0135] Examples of the suitable antiseptics include a paraoxybenzoate, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid, and the like.

[0136] Examples of the suitable antioxidants include a sulfide, an ascorbate, and the like.

[0137] Examples of the suitable coloring agents include water-soluble, edible tar pigments (e.g., edible pigments such as Edible Red Nos. 2 and 3, Edible Yellow Nos. 4 and 5, and Edible Blue Nos. 1 and 2, water-insoluble lake pigments (e.g., an aluminum salt of the aforementioned water-soluble, edible tar pigment, and the like), natural pigments (β -carotene, chlorophyll, red iron oxide, and the like).

[0138] Examples of the suitable sweeteners include sodium saccharate, dipotassium glycyrrhizinate, aspartame, stevia, and the like.

[0139] Dosage forms of the aforementioned pharmaceutical composition include oral agents such as tablets, capsules (including soft capsules and microcapsules), granules, powders, syrups, emulsions, and suspensions; non-oral agents such as injections (e.g., subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections, and the like), external agents (e.g., nasal preparations, transdermal preparations, ointments, and the like), suppositories (e.g., rectal suppositories, vaginal suppositories, and the like), pellets, drip infusions, sustained-release preparations (e.g., sustained-release microcapsules, and the like), etc. These are safely administered orally or non-orally.

[0140] The pharmaceutical composition can be produced by a conventional method in the preparation technique field, for example, by a method described in Japanese Pharmacopoeia, or the like. Hereinafter, a method for specifically producing a preparation will be set forth in detail. The content of the compound in the pharmaceutical composition, obtained by the screening method of the present invention, varies depending on the dosage form, the dose of the compound, etc.; and it is for example from about 0.1 to 100% by weight.

[0141] For instance, an oral agent is produced by adding to an effective ingredient an excipient (e.g., lactose, saccharose, starch, D-mannitol, or the like), a disintegrator (e.g., calcium carboxymethyl cellulose, or the like), a binder (e.g., gelatinized starch, gum arabic, carboxymethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, or the like), a lubricant (e.g., talc, magnesium stearate, polyethylene glycol 6000, or the like), etc., compression molding the resultant mixture, and subsequently, as required, coating the resulting material with a coating base by a publicly known method for the purpose of masking of a taste, solubility in intestines or durability.

[0142] The coating base includes, for example, a sugar-coating base, a water-soluble film coating base, an enteric film coating base, a sustained-release film coating base, and the like.

[0143] The sugar-coating bases for use includes saccharose, and further may include one species or two or more species in combination selected from the group consisting of talc, precipitated calcium carbonate, gelatin, gum arabic, pullulan, carnauba wax, and the like.

[0144] The water-soluble film coating base includes, for example, cellulose base polymers such as hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, and methylhydroxyethyl cellulose; synthetic polymers such as polyvinylacetal diethylaminoacetate, aminoalkylmethacrylate copolymer E (Eudragit-E (trade name), Rohm Pharma Corp.), and polyvinyl pyrrolidone; polysaccharides such as pullulan; and the like.

[0145] The enteric film coating base includes, for example, cellulose base polymers such as hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, carboxymethylethyl cellulose, and cellulose acetate phthalate; acrylic acid base polymers such as Methacrylic Acid Copolymer L (Eudragit-L (trade name), Rohm Pharma Corp.), Methacrylic Acid Copolymer LD (Eudragit-L-30D55 (trade name), Rohm Pharma Corp.), and Methacrylic Acid Copolymer S (Eudragit-S (trade name), Rohm Pharma Corp.); natural substances such as shellac.

[0146] The sustained-release film coating base includes, for example, cellulose base polymers such as ethyl cellulose; acrylic acid base polymers such as Aminoalkyl Methacrylate Copolymer RS (Eudragit-RS (trade name), Rohm Pharma Corp.), and an ethyl acrylate-methylmethacrylate copolymer suspension (Eudragit-NE (trade name), Rohm Pharma Corp.); and the like.

[0147] The above-mentioned coating bases may also be used in a mixture of two or more species thereof in a suitable ratio. Also, when coating, for example, sunproofing agents such as titanium oxide and diiron trioxide may be used as well.

[0148] An injection is produced by dissolving, suspending or emulsifying an effective ingredient in an aqueous solvent

(e.g., distilled water, physiological saline, Ringer's solution, and the like), an oily solvent (e.g., vegetable oils such as olive oil, sesame oil, cottonseed oil, corn oil, propylene glycol, or the like), or the like, together with a dispersing agent (e.g., polysorbate 80, polyoxyethylene hardened castor oil, or the like, polyethylene glycol, carboxymethyl cellulose, sodium alginate, or the like), a preservative (e.g., methylparaben, propylparaben, benzyl alcohol, chlorobutanol, phenol, or the like), an isotonicizing agent (e.g., sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose, or the like), or the like. At this time, if desired, additives such as a solubilizing agent (e.g., sodium salicylate, sodium acetate, or the like), a stabilizer (e.g., human serum albumin, or the like), a soothing agent (e.g., benzyl alcohol, or the like), and the like may also be used. An injection solution is normally packed in a suitable ampule.

[0149] A preparation thus obtained is safe and low in toxicity, and thus can be orally or non-orally administered to, for example, mammals (e.g., a human, a mouse, a rat, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.).

[0150] The dose of a prophylactic and therapeutic product for diseases associated with the protein of the present invention varies depending on a target disease, a target to be administered, a route for administration, or the like. For example, with an adult patient (body weight : 60 kg) suffering from a renal disease, the dose is from about 0.1 to about 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, per day as an effective ingredient, i.e., a compound obtained by the screening method of the present invention.

[0151] An antibody to the protein of the present invention can be produced in accordance with a method of producing publicly known antibody or antiserum using the protein as an antibody. A monoclonal antibody or a polyclonal antibody to the protein of the present invention can be produced, for example, as explained below.

[Preparation of Monoclonal Antibody]

(a) Preparation of Monoclonal Antibody-producing Cell

[0152] The protein of the present invention is administered to a warm-blooded animal either solely or along with a carrier or a diluent to a site where the administration makes it possible to produce an antibody. In order to enhance antibody productivity when administration, a complete Freund's adjuvant or an incomplete Freund's adjuvant may be administered. The administration is normally performed once in two to six weeks and 2 to 10 times in total. The warm-blooded animals to be used include, for example, mammals (or a chicken and the like besides mammals) such as a monkey, a rabbit, a dog, a guinea pig, a mouse, a rat, a sheep, a goat, and the like, with a mouse and a rat being preferably used.

[0153] For instance, a monoclonal antibody-producing hybridoma can be prepared by a method that involves selecting a warm-blooded animal immunized with an antigen, e.g., a mouse that has indicated the antibody titer, collecting the spleen or lymph node two to five days after the final immunization, and then fusing an antibody-producing cell contained therein with a myeloma cell of the same or different animal species. The antibody titer in an antiserum is measured, for example, by reacting the labeled protein to be described below with the antiserum and then determining the activity of the labeling agent bound to the antibody. The fusing operation can be conducted according to publicly known methods, for example, the method of Kohler and Milstein (Nature, 256, 495, 1975). The fusing promoters include, for example, polyethylene glycol (PEG), Sendai virus, and the like, with PEG being preferably used.

[0154] The myeloma cell includes, for example, that of a warm-blooded animal such as NS-1, P3U1, SP2/0, AP-1, and the like, with P3U1 being preferably used. A preferred ratio of the number of antibody-producing cells to be used (spleen cells) to that of myeloma cells is from about 1:1 to about 20:1; PEG (preferably PEG 1000 to PEG 6000) is added in a concentration of from about 10 to about 80%, followed by incubating at about 20 to about 40°C, preferably at about 30 to about 37°C for about 1 to about 10 minutes, thereby being capable of efficiently fusing the cells.

[0155] A monoclonal antibody-producing hybridoma can be screened, for example, by a method that include adding the supernatant of a hybridoma culture to a solid phase (e.g., microplate) adsorbed with a protein antigen directly or together with a carrier, adding an anti-immunoglobulin antibody (when a mouse cell is used for cell fusion, an anti-mouse immunoglobulin antibody is used) labeled with a radioactive substance or an enzyme, or Protein A, and then detecting the monoclonal antibody bound to the solid phase; by a method that involves adding the supernatant of a hybridoma culture to a solid phase adsorbed with an anti-immunoglobulin antibody or Protein A, adding a protein labeled with a radioactive substance or an enzyme, and subsequently detecting the monoclonal antibody bound to the solid phase; or by a similar method.

[0156] A monoclonal antibody can be selected by publicly known methods or by analogous methods thereto. Selection of a monoclonal antibody can be normally carried out in a medium for animal cells to which HAT (hypoxanthine, aminopterin and thymidine) is added. The medium for selection and growth of a monoclonal antibody may be any medium as long as a hybridoma can grow therein. The medium to be used includes, for example, a RPMI 1640 medium containing 1 to 20%, preferably 10% to 20% of a fetal bovine serum, a GIT medium (Wako Pure Chemical Industries, Ltd.) containing 1 to 10% of a fetal bovine serum, a serum free medium for cultivation of a hybridoma (SFM-101, Nissui

Seiyaku Co., Ltd.), and the like. The culture temperature is normally at from 20 to 40°C, preferably at about 37°C. The culture period is usually for 5 days to 3 weeks, preferably 1 week to 2 weeks. The cultivation can be conducted normally in a 5% carbon dioxide gas. The antibody titer of the culture supernatant of a hybridoma can be determined in a similar way to the determination of the antibody titer in an antiserum as discussed above.

[0157] The monoclonal antibody thus obtained can be separated and purified in accordance with publicly known methods, for example, a method of separating and purifying an immunoglobulin [e.g., salting-out, alcohol precipitation, isoelectric point precipitation, electrophoresis, adsorption and desorption with an ion exchanger (e.g., DEAE), ultracentrifugation, gel filtration, or a specific purification method that involves collecting only an antibody with an antigen-binding solid phase or an activated adsorbent such as Protein A, Protein G, or the like, and subsequently dissociating the binding to yield the antibody].

[Preparation of Polyclonal Antibody]

[0158] A polyclonal antibody against the protein of the present invention can be produced according to publicly known methods, for example, according to a method that involves making an immunogen (antigen of a protein) itself or its complex with a carrier protein; immunizing a warm-blooded animal in a similar way to the above-described method of producing a monoclonal antibody; collecting a product containing an antibody to the protein of the present invention from the immunized animal; and then separating and purifying the antibody.

[0159] With a complex of an immunogen with a carrier protein used to immunize a warm-blooded animal, the kind of the carrier protein and the mixing ratio of a carrier to hapten may arbitrarily be chosen, as long as an antibody is efficiently produced for the hapten immunized by crosslinking to the carrier. For example, a method is used that couples bovine serum albumin, bovine thyroglobulin, hemocyanin, or the like with hapten in a weight ratio of from about 0.1 to about 20:1, preferably from about 1 to 5:1.

[0160] In addition, in the coupling of hapten with a carrier, employed are a variety of condensing agents, e.g., glutaraldehyde; carbodiimide; a maleimide activated ester, an activated ester reagent containing a thiol group, a dithiopyridyl group, or the like; etc.

[0161] A condensation product is administered to a warm-blooded animal either solely or along with a carrier or a diluent to a site where an antibody can be produced by administration.

[0162] In order to enhance antibody productivity when administration, a complete Freund's adjuvant or an incomplete Freund's adjuvant may be administered. The administration is normally made once approximately in 2 to 6 weeks and about 3 to about 10 times in total.

[0163] A polyclonal antibody can be collected from blood, ascites, or the like of a warm-blooded animal immunized by the above-described method, preferably from blood of the mammal.

[0164] Determination of the polyclonal antibody titer in an antiserum can be made in a similar way to that of the antibody titer in an antiserum as discussed above. Separation and purification of a polyclonal antibody can be carried out in accordance with the method of separating and purifying an immunoglobulin similar to the method of separating and purifying the aforementioned monoclonal antibody.

[0165] An antibody to the protein of the present invention can be inactivated (neutralized) by binding it to the protein or salts thereof of the present invention, and thus can be utilized as a prophylactic and therapeutic product for diseases associated with the protein of the present invention as well.

[0166] The prophylactic and therapeutic product may be an antibody itself to the protein of the present invention, but a pharmaceutical composition obtained by admixing the antibody with a pharmaceutically acceptable carrier is preferable. Here, the pharmaceutically acceptable carrier includes a similar carrier to that employed in the above-mentioned "prophylactic and therapeutic product for diseases associated with the protein of the present invention".

[0167] The pharmaceutical composition can be produced in a similar manner to that in the aforementioned "prophylactic and therapeutic product for diseases associated with the protein of the present invention".

[0168] A preparation thus obtained is safe and low in toxicity, and thus can be orally or non-orally administered to, for example, mammals (e.g., a human, a mouse, a rat, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.).

[0169] The dose of a prophylactic and therapeutic product for diseases associated with the protein of the present invention varies depending on a target disease, a target to be administered, a route for administration, or the like. For example, with an adult patient (body weight: 60 kg) suffering from a renal disease, the dose is from about 0.1 to 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, per day as an effective ingredient, i.e., an antibody to the protein of the present invention.

[0170] The protein of the present invention increases in expression, for example, for renal diseases (e.g., diabetic nephropathy) and the like, and so is useful as a marker in renal diseases for an early diagnosis, criteria for the severity of a symptom, and the prognostication of disease progress. Accordingly, an antibody to the protein of the present invention can also be employed as a diagnostic product for diseases associated with the protein of the present invention.

[0171] In other words, the present invention provides:

- (i) a method for diagnosing a disease associated with the protein or salts thereof of the present invention, characterized in that the protein or salts thereof of the present invention in a test solution is quantified by competitively reacting an antibody, the test solution and the labeled protein of the present invention and by determining the ratio of the labeled protein bonded to the antibody; and
- (ii) a method for diagnosing a disease associated with the protein or salts thereof of the present invention, characterized in that after a test solution, an unsolubilized antibody of the present invention on a carrier and another labeled antibody of the present invention are reacted at the same time or continuously, the protein or salts thereof in the test solution is quantified by determining the activity of the labeled agent on the unsolubilized carrier.

[0172] In the quantification of (ii) described above, when one antibody is an antibody that recognizes the N terminal region of the protein of the present invention, the other antibody is desirably an antibody that recognizes the other portion, e.g., the C terminal region, of the protein of the present invention.

[0173] Also, in addition to being capable of quantitatively determining the protein of the present invention using the monoclonal antibody to the protein, the detection by tissue staining or the like can also be carried out. For these objects, an antibody molecule itself may be used, or a F(ab')₂, Fab' or Fab fraction of an antibody molecule may be utilized as well.

[0174] The quantification of the protein or salts thereof of the present invention using the antibody of the present invention is not particularly limited. Any determination methods may be used as long as they involve detecting by chemical or physical means the amount of an antibody, an antigen or an antibody-antigen complex corresponding to that of an antigen in a solution measured, and then calculating the amount from a standard curve prepared from standard solutions containing known amounts of antigens. For example, nephrometry, the competitive method, the immunometric method, and the sandwich method are suitably used. The sandwich method discussed below is most preferable from the viewpoint of sensitivity and specificity.

[0175] The labeling agent used in determination methods using labeled substances, to be used, include, for example, a radioisotope, an enzyme, a fluorescent substance, a luminescent substance, and the like. The radioisotope for use includes, for example, [¹²⁵I], [¹³¹I], [³H], [¹⁴C], and the like. The aforementioned enzyme for use is preferably stable and high in specific activity, and includes, for example, β -galactosidase, β -glucosidase, an alkaline phosphatase, a peroxidase, malate dehydrogenase, and the like. The fluorescent substance for use includes, for example, fluorescamine, fluorescein isothiocyanate, and the like. The luminescent substance for use includes, for example, luminol, a luminol derivative, luciferin, lucigenin, and the like. Furthermore, the biotin-(strepto) avidin system can be also used for binding an antibody or an antigen to the labeling agent.

[0176] In insolubilization of an antigen or antibody, employed is physical adsorption, or a method using chemical bonding normally used for insolubilization or immobilization of a protein. The carrier includes insoluble polysaccharides such as agarose, dextran, cellulose; synthetic resins such as polystyrene, polyacrylamide, silicon; glass; and the like.

[0177] The sandwich method involves means that includes reacting an insolubilized monoclonal antibody of the present invention with a test solution (primary reaction), further reacting the resultant material with another labeled monoclonal antibody of the present invention (secondary reaction), and subsequently determining the activity of the labelling agent on the insolubilized carrier to whereby be capable of quantifying the protein or salts thereof of the present invention in the test solution. The order of the primary and secondary reactions may be reversed, and the reactions may be carried out simultaneously or with an interval. The labeling agent and the immobilization method can be conducted in accordance with those described above. In addition, in the immunoassay by the sandwich method, an antibody used for an immobilized or labeled antibody is not necessarily one species, but a mixture of two or more species of antibodies may be used in order to improve determination sensitivity.

[0178] In the determination method of the protein or salts thereof of the present invention by the sandwich method, monoclonal antibodies of the present invention used in the primary and secondary reactions are preferably those whose binding sites by the protein of the present invention are different. That is, for antibodies used in the primary and secondary reactions, for example, when an antibody used in the secondary reaction recognizes the C terminal region of the protein of the present invention, an antibody used in the primary reaction preferably recognizes a region exclusive of the C terminal region, e.g. the N terminal region.

[0179] A monoclonal antibody of the present invention can be used for determination systems other than the sandwich method, for example, for the competitive method, the immunometric method, nephrometry, and the like.

[0180] The competitive method comprises competitively reacting antigens and labeled antigens in a test solution with antibodies, separating the unreacted labeled antigens (F) from the labeled antigens bound to the antibodies (B) (B/F separation), determining the labeled amount of either of B and F and then quantifying the amount of antigens in the test solution. As this reaction method, employed are a liquid phase method using a soluble antibody as an antibody and using polyethylene glycol and the secondary antibody to the aforementioned antibody or the like for B/F separation,

and an immobilized method using an immobilized antibody as the primary antibody, or using a soluble antibody as the primary antibody and using an immobilized antibody as the secondary antibody.

[0181] The immunometric method includes competitively reacting antigens in a test solution and immobilized antigens with a specified amount of labeled antibodies, and then separating the immobilized phase from the liquid phase, or includes reacting antigens in a test solution with an excess amount of labeled antibodies, adding immobilized antigens to bind the unreacted labeled antibodies to the immobilized phase, separating the immobilized phase from the liquid phase. Then, the labeled amount in either phase is determined to quantify the amount of antigens in the test solution.

[0182] Additionally, the nephrometry determines the amount of insoluble precipitates produced as a result of the antigen-antibody reaction in gel or solution. Even when the amount of antigens in a test solution is small and only a small amount of precipitates is obtained, laser nephrometry using laser scattering is advantageously employed.

[0183] Application of these individual immunological determination methods to the quantification methods of the present invention does not require the setting of any particular conditions, procedures, and the like. A system for determining the protein of the present invention can be constructed by the addition of the usual technical consideration of a person skilled in the art to the conventional conditions and procedures. For details of these general technical means, review articles, texts, and the like can be referred.

[0184] The references include, for example, Hiroshi Irie, ed. "Radioimmunoassay" (Kodansha, published in 1974), Hiroshi Irie, ed. "Sequel to the Radioimmunoassay" (Kodansha, published in 1979), Eiji Ishikawa, et al. ed. "Enzyme Immunoassay" (Igakushoin, published in 1978), Eiji Ishikawa, et al. ed. "Immunoenzyme Assay" (2nd ed.) (Igakushoin, published in 1982), Eiji Ishikawa, et al. ed. "Immunoenzyme Assay" (3rd ed.) (Igakushoin, published in 1987), Methods in ENZYMOLOGY, Vol. 70 (Immunochemical Techniques (Part A)), *ibid.*, Vol. 73 (Immunochemical Techniques (Part B)), *ibid.*, Vol. 74 (Immunochemical Techniques (Part C)), *ibid.*, Vol. 84 (Immunochemical Techniques (Part D: Selected Immunoassays)), *ibid.*, Vol. 92 (Immunochemical Techniques (Part E: Monoclonal Antibodies and General Immunoassay Methods)), *ibid.*, Vol. 121 (Immunochemical Techniques (Part I: Hybridoma Technology and Monoclonal Antibodies))(all published by Academic Press Publishing).

[0185] As discussed so far, use of the antibody of the present invention enables the protein or salts thereof of the present invention to be highly sensitively quantified.

[0186] In the above-described quantification methods using the antibody of the present invention, when an excessive increase or decrease of the protein of the present invention is detected by quantifying the concentration of the protein or the salts thereof in a biopsy sample (e.g., renal cells, or the like) of a test animal, for example, the animal can be diagnosed as being infected by a disease associated with the protein or salts thereof of the present invention such as a renal disease, or it can be diagnosed as being highly possibly infected in the future.

[0187] The present invention further relates to a screening method for a prophylactic and therapeutic substance for diseases associated with the protein of the present invention, which is characterized by using a polynucleotide (hereafter, may be abbreviated as polynucleotide of the present invention) comprising a base sequence or a partial sequence thereof encoding the protein of the present invention.

[0188] The nucleotide of the present invention may be any nucleotide as long as it comprises a base sequence (DNA or RNA, preferably DNA) encoding the protein of the present invention or a partial sequence thereof. The polynucleotides include DNA encoding the protein of the present invention and RNA such as mRNA, and these may be either a double strand, or a single strand. When the nucleotide is double-stranded, it may be double-stranded DNA, double-stranded RNA or a hybrid of DNA and RNA. If the nucleotide is single-stranded, it may be either a sense strand (i.e., coding strand) or an antisense strand (i.e., non-coding strand). DNA encoding the protein of the present invention includes the above.

[0189] The nucleotide of the present invention may be a free form or a salt, or an amide form or an ester form. The salts include salts similar to salts of the protein of the present invention. The amide and ester forms include compounds of which terminal phosphorous groups are amidated or esterified.

[0190] The screening method using the polynucleotide of the present invention is carried out, for example, by comparing the level of RNA encoding the protein of the present invention in the case where a cell having the capability of producing the protein of the present invention is cultivated and the case where a cell having the capability of producing the protein of the present invention is cultivated in the presence of a test compound; and the like.

[0191] Here, the cell having the capability of producing the protein of the present invention, the method of cultivating the cell, and the test compound includes similar ones to those employed in the above-described screening method using the protein of the present invention.

[0192] RNA encoding the protein of the present invention can be quantified in accordance with publicly known methods, e.g., the method described in Molecular Cloning 2nd (J. Sambrook et al., Cold Spring Harbor Lab. Press, 1989) or an analogous method thereto. For example, the RNA can be quantified in accordance with publicly known methods, e.g., Northern Hybridization that uses as a probe a nucleic acid comprising a base sequence or a partial sequence thereof represented by SEQ ID NO: 3 or SEQ ID NO: 4; the PCR method that utilizes as a primer a nucleic acid

comprising a partial sequence of a base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4 or an analogous method thereto; and the like.

[0193] For example, a test compound that increases the level of RNA (preferably, mRNA) encoding the protein of the present invention by about 20% or more, preferably 30% or more, more preferably about 50% or more, can be selected as a compound that promotes the expression of RNA encoding the protein of the present invention; a test compound that decreases the level of RNA (preferably, mRNA) encoding the protein of the present invention by about 20% or more, preferably 30% or more, more preferably about 50% or more, can be selected as a compound that inhibits the expression of RNA encoding the protein of the present invention.

[0194] The prophylactic and therapeutic substance for diseases associated with the proteins of the present invention, obtained by the screening method using the polynucleotides of the present invention may include any of a peptide, a protein, a non-peptide compound, a synthetic compound, a fermented product, a cell extract, a plant extract, an animal tissue extract, plasma, and the like. These may form salts, and the salts include, for example, those similar to the salts of the aforementioned protein of the present invention.

[0195] The prophylactic and therapeutic substance for diseases associated with the protein of the present invention, obtained by the screening method can be used as a prophylactic and therapeutic product for diseases associated with the protein of the present invention after processing into a pharmaceutical composition by admixing, as required, with a pharmaceutically acceptable carrier.

[0196] Here, the pharmaceutically acceptable carrier includes a similar carrier to that employed in the prophylactic and therapeutic substance for diseases associated with the protein of the present invention, obtained by the screening method using the protein of the present invention.

[0197] The pharmaceutical composition can be produced in a similar to that in the prophylactic and therapeutic substance for diseases associated with the protein of the present invention, obtained by the screening method using the protein of the present invention.

[0198] A preparation thus obtained is safe and low in toxicity, and thus can be orally or non-orally administered to, for example, mammals (e.g., a human, a mouse, a rat, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.).

[0199] The dose of a prophylactic and therapeutic product for diseases associated with the protein of the present invention varies depending on a target disease, a target to be administered, a route for administration, or the like. For example, with an adult patient (body weight : 60 kg) suffering from a renal disease, the dose is from about 0.1 to about 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, per day as an effective ingredient, i.e., a compound obtained by the screening method of the present invention.

[0200] The prophylactic and therapeutic substance for diseases associated with the protein of the present invention can be also screened by detection of the promoter activity of a gene encoding the protein.

[0201] In a cell or a non-human mammal wherein DNA encoding the protein of the present invention is substituted for a reporter gene, in which the reporter gene is present under the control of the promoter of a gene encoding the protein of the present invention, confirmation of the expression of the substance encoded by the reporter gene after treatment by a test compound or administration thereof permits the detection of the activity of the promoter.

[0202] In addition, in a cell or a non-human mammal having a vector produced by linking the transcription regulating region of a gene encoding the protein of the present invention with a reporter gene as well, the activity of the promoter can be detected.

[0203] The reporter gene includes, for example, a β -galactosidase gene (lacZ), a soluble alkaline phosphatase gene, a luciferase gene, and the like.

[0204] For example, when a part of a DNA area encoding the protein of the present invention is replaced by a β -galactosidase gene (lacZ) derived from Escherichia coli, fundamentally, a β -galactosidase is expressed instead of the protein of the present invention in a tissue in which the protein of the present invention expresses. Hence, staining by means of a reagent that becomes a substrate of a β -galactosidase such as 5-bromo-4-chloro-3-indolyl- β -galactopyranoside (X-gal) can conveniently confirm the expression state of the protein of the present invention. Specifically, a cell or a tissue fragment is immobilized by glutaraldehyde or the like, and the resulting material is washed with a phosphate buffer saline (PBS), and then it is reacted in a staining solution containing X-gal at room temperature or near 37°C for about 30 minutes to about 1 hour. Thereafter, the tissue sample is washed with a 1 mM EDTA/PBS solution to stop the β -galactosidase reaction and then the coloring is observed, and thereby the expression state of the protein of the present invention in the cell or the tissue can be confirmed. Also, according to the usual method, mRNA encoding a lacZ may be detected as well.

[0205] A compound that promotes or inhibits the promoter activity of a gene encoding the protein of the present invention, which regulates the expression of the protein and the activity of the protein, is useful as a prophylactic and therapeutic product for diseases associated with the protein of the present invention.

[0206] An antisense nucleotide of DNA encoding the protein of the present invention, which inhibits translation into the protein by hybridizing a polynucleotide encoding the protein of the present invention, is useful as a prophylactic

and therapeutic product for diseases associated with the protein of the present invention as in the case of a compound obtained by the screening method of the present invention.

[0207] Here, the antisense nucleotide is any one as long as it has complementary or substantially complementary base sequence to a base sequence of DNA encoding the protein of the present invention, or a partial sequence thereof, and has the expression suppression action on the DNA, with an antisense DNA being preferable.

[0208] The base sequence substantially complementary to a base sequence of DNA encoding the protein of the present invention includes, for example, base sequences that have about 70% or more, preferably about 80% or more, more preferably about 90% or more, most preferably about 95% or more identity to a complete base sequence or a partial base sequence thereof of a base sequence (i.e., a complementary chain of DNA encoding the protein of the present invention) complementary to the base sequence of the DNA, and the like. In particular, antisense nucleotides are preferable that have about 70% or more, preferably about 80% or more, more preferably about 90% or more, and most preferably about 95% or more identity to a complementary chain of a base sequence (e.g., a base sequence near the initiation codon, or the like) of a portion encoding the N terminal region of the protein of the present invention among the complete base sequence of the complementary chain of DNA encoding the protein.

[0209] Specifically, the antisense nucleotides include antisense nucleotides having complementary or substantially complementary base sequence to a bases sequence of DNA comprising a base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4, or a portion thereof; preferably, antisense nucleotides having a base sequence complementary to a base sequence comprising a base sequence represented by SEQ ID NO: 3 or SEQ ID NO: 4, or a portion thereof; and the like.

[0210] The number of constitution bases of the antisense nucleotide is not particularly limited so long as it inhibits translation into the protein of the present invention by uniquely hybridizing with a polynucleotide encoding the protein, with the number being normally from about 10 to about 40, preferably from about 15 to about 30.

[0211] For the purpose of prevention of decomposition by a hydrolase such as a nuclease, a phosphate of each nucleotide constituting an antisense nucleotide may be replaced by, for example, a chemically modified phosphate such as a phosphonothioate, a methylphosphonate, or phosphonodithioate. In addition, a deoxyribose of each nucleotide may be replaced by a chemically modified deoxyribose of 2'-O-methylation or the like; is subjected to chemical modification in a base portion (pyrimidine or purine) as well; and may also be any deoxyribose as long as it is hybridized with DNA having the base sequence represented by SEQ ID NO: 2. These antisense nucleotides can be produced by means of publicly known DNA synthesis apparatus, or the like.

[0212] The antisense nucleotide of DNA encoding the protein of the present invention is low in toxicity, which can suppress in the body the function (e.g., thyroxine de^{5'}-iodination enzyme activity) of the protein of the present invention or DNA encoding the protein, can be used as, for example, a prophylactic and therapeutic product for diseases associated with the protein of the present invention. The antisense nucleotide can be orally or non-orally administered to mammals (e.g., a human, a mouse, a rat, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.) after processing into a preparation in a similar manner to that in the case of the prophylactic and therapeutic substance for diseases associated with the protein of the present invention obtained by the screening method using the protein of the present invention. Also, the antisense nucleotide can also be administered after it is inserted into an appropriate vector such as a retrovirus vector, an adenovirus vector, an adenovirus associated virus vector, or the like.

[0213] The antisense nucleotide may be administered with a gene gun or a catheter such as a hydrogel catheter, or can also be locally administered into the trachea as an inhalation agent after being made sol.

[0214] The dose of the antisense nucleotide varies depending on a target disease, a target to be administered, a route for administration, or the like. For example, with an adult patient (body weight: 60 kg) suffering from a renal disease, the dose is from about 0.1 to about 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, per day.

[0215] Furthermore, an antisense nucleotide of DNA encoding the protein of the present invention can also be employed as a diagnostic oligonucleotide probe for examining the presence and the expression state of the DNA in a tissue or a cell.

[0216] As well as the above-described antisense polynucleotide, a double-stranded RNA comprising a part of RNA encoding the protein of the present invention, a ribozyme comprising a portion of RNA encoding the protein of the present invention, or the like can suppress the function of the protein of the present invention or DNA encoding the protein, and therefore can be used as, e.g., a prophylactic and therapeutic product for renal diseases, or the like.

[0217] Here, the double-stranded RNA can be produced by designing on the basis of a sequence of a polynucleotide of the present invention in accordance with publicly known methods, for example, the method described in Nature, 411, 494, 2001.

[0218] The ribozyme can be produced by designing on the basis of a sequence of a polynucleotide of the present invention in accordance with publicly known methods, for example, the method described in TRENDS in Molecular Medicine, 7, 221, 2001. For example, connection of a publicly known ribozyme to a portion of RNA encoding the protein

of the present invention enables production of a desired ribozyme. The portion of RNA encoding the protein of the present invention includes a portion (RNA fragment) next to a cleaved region of RNA of the present invention capable of being excised by a publicly known ribozyme.

5 [0219] When the above-mentioned double-stranded RNA or ribozyme is used as a prophylactic and therapeutic product for diseases associated with the protein of the present invention, it can be formulated as for the above-described antisense polynucleotide for administration.

[0220] A polynucleotide of the present invention, which can detect abnormality (gene abnormality) of DNA or mRNA encoding the protein of the present invention in mammals (e.g., a human, a rat, a mouse, a guinea pig, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.) by being used as a probe, is useful as a
10 gene diagnosis agent of, e.g., damage to, or mutation or expression decrease of the DNA or mRNA, an increase in or expression excess of the DNA or mRNA, or the like.

[0221] The aforementioned gene diagnosis using the polynucleotide of the present invention can be carried out, for example, by publicly known northern hybridization or the PCR-SSCP method (Genomics), Vol. 5, pp. 874-879 (1989),
15 Proceeding of the National Academy of Sciences of the United States of America, Vol. 86, pp. 2766-2770 (1989), or the like.

[0222] For example, when expression excess or decrease is detected by northern hybridization, or if a mutation is detected by the PCR-SSCP method, for example, the subject can be diagnosed as being infected with a disease associated with the protein of the present invention such as a renal disease, or having a high possibility of being infected with the disease in the future.

20 [0223] The present invention further relates to a prophylactic and therapeutic product for diseases associated with the protein of the present invention, characterized by comprising a polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6. Here, the polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 is a decoy nucleotide for DNA to which the protein of the present invention bonds.

[0224] The polynucleotide can be produced in accordance with publicly known methods.

25 [0225] The polynucleotide, which is low in toxicity, and which can suppress the function of the protein of the present invention or DNA encoding the protein (e.g., a transcription controlling activity of a fibrosis relating gene, a cell cycle relating gene and a thrombus relating gene) in the body, can be used as a prophylactic and therapeutic product for diseases associated with the protein of the present invention. The polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6 can be orally or non-orally administered to mammals (e.g., a human, a mouse, a
30 rat, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.) after processing into a preparation in a similar manner to that in the case of the prophylactic and therapeutic substance for diseases associated with the protein of the present invention obtained by the screening method using the protein of the present invention.

[0226] In addition, the polynucleotide can also be administered after it is inserted into an appropriate vector such as a retrovirus vector, an adenovirus vector, an adenovirus associated virus vector, or the like.

35 [0227] The polynucleotide may be administered with a gene gun or a catheter such as a hydrogel catheter, or can also be locally administered into the trachea as an inhalation agent after being made sol.

[0228] The dose of the prophylactic and therapeutic product for diseases associated with the protein of the present invention varies depending on a target disease, a target to be administered, a route for administration, or the like. For example, with an adult patient (body weight : 60 kg) suffering from a renal disease, the dose is from about 0.1 to about
40 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, per day as an effective ingredient, i.e., a nucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6.

[0229] The present invention further relates to a prophylactic and therapeutic product for diabetic nephropathy comprising a suppressor of Egr-1.

45 [0230] The suppressor of Egr-1 is not particularly limited as long as it is a substance capable of suppressing production or expression of Egr-1, or the activity of Egr-1 in the body, and may be any of a peptide, a protein, a non-peptide compound, a synthetic compound, a fermented product, a cell extract, a plant extract, an animal tissue extract, plasma, or the like. These may form salts, and examples of the salt include salts similar to those of the protein of the present invention described above.

[0231] The suppressor of Egr-1 is preferably a substance capable of suppressing production or expression of Egr-1, or the activity of Egr-1 in kidneys, and thus a suppressor of renal Egr-1.
50

[0232] The suppressor of Egr-1 may also be a substance capable of suppressing production or expression of factors such as a fibrosis relating gene, a cell cycle relating gene, and a thrombus relating gene in the body, or suppressing the activities of the factors.

55 [0233] Here, the fibrosis relating gene, the cell cycle relating gene, and the thrombus relating gene include those illustrated as the above-mentioned "substantially the same activity."

[0234] A prophylactic and therapeutic product for diabetic nephropathy can be formulated as for the prophylactic and therapeutic substance for diseases associated with the protein of the present invention.

[0235] The prophylactic and therapeutic product for diabetic nephropathy is safe and low in toxicity, and thus can be

orally or non-orally administered to, for example, mammals (e.g., a human, a mouse, a rat, a rabbit, a sheep, a pig, a bovine, a horse, a cat, a dog, a monkey, a chimpanzee, etc.).

[0236] The dose of the prophylactic and therapeutic product for diabetic nephropathy of the present invention varies depending on a target disease, a target to be administered, a route for administration, or the like. For example, with an adult patient (body weight: 60 kg), the dose is from about 0.1 to about 100 mg, preferably from about 1.0 to about 50 mg, more preferably from about 1.0 to about 20 mg, per day as an effective ingredient, i.e., a suppressor of Egr-1.

[0237] Herein, representation of a base, an amino acid, or the like by a code is in accordance with a code based on IUPAC-IUB Commission on Biochemical Nomenclature or a conventional code in the art, with examples thereof being indicated below. Also, when an optical isomer on an amino acid is present, it indicates the L form unless otherwise indicated.

DNA :	deoxyribonucleic acid
cDNA :	complementary deoxyribonucleic acid
A :	adenine
T :	thymine
G :	guanine
C :	cytosine
RNA :	ribonucleic acid
mRNA :	messenger ribonucleic acid
dATP :	deoxyadenosine triphosphate
dTTP :	deoxythymidine triphosphate
dGTP :	deoxyguanosine triphosphate
dCTP :	deoxycytidine triphosphate
ATP :	adenosine triphosphate
EDTA :	ethylenediaminetetraacetic acid
SDS :	sodium dodecyl sulfate
Gly :	glycine
Ala :	alanine
Val :	valine
Leu :	leucine
Ile :	isoleucine
Ser :	serine
Thr :	threonine
Cys :	cysteine
Met :	methionine
Glu :	glutamic acid
Asp :	aspartic acid
Lys :	lysine
Arg :	arginine
His :	histidine
Phe :	phenylalanine
Tyr :	tyrosine
Trp :	tryptophan
Pro :	proline
Asn :	asparagine
Gln :	glutamine
PGlu :	pyroglutamic acid
Sec :	selenocysteine

[0238] The sequence identification numbers in the sequence listing of the description indicates the sequences below.

[SEQ ID NO: 1]

This represents a partial sequence of amino acid sequences of Egr-1 preserved in a human, a mouse and a rat.

[SEQ ID NO: 2]

This represents an amino acid sequence of human Egr-1.

[SEQ ID NO: 3]

This represents a base sequence of DNA encoding human Egr-1 having an amino acid sequence represented by SEQ ID NO: 2.

[SEQ ID NO: 4]

This represents a base sequence of DNA encoding human Egr-1 having an amino acid sequence represented by SEQ ID NO: 2.

[SEQ ID NO: 5]

5 This represents a base sequence of a decoy nucleotide of Egr-1.

[SEQ ID NO: 6]

This represents a base sequence of a decoy nucleotide of Egr-1.

[SEQ ID NO: 7]

This represents a base sequence of Egr-1 antisense oligonucleotide.

10 [SEQ ID NO: 8]

This represents a base sequence of a primer to amplify Egr-1 cDNA.

[SEQ ID NO: 9]

This represents a base sequence of a primer to amplify Egr-1 cDNA.

[SEQ ID NO: 10]

15 This represents a base sequence of a sense strand of double-stranded DNA capable of binding to Egr-1.

[SEQ ID NO: 11]

This represents a base sequence of a sense strand of double-stranded DNA not capable of binding to Egr-1.

20 [0239] Hereinafter, the present invention will in more detail be set forth in terms of the EXAMPLES and EXPERIMENTAL EXAMPLES. However, the present invention should not be limited thereto.

EXAMPLES

EXPERIMENTAL EXAMPLE 1

25

Increase in the early growth response-1 (Egr-1) mRNA expression in the kidney of Wistar fatty rats

30 [0240] Using 13, 22 and 40-week-old male Wistar fatty rats (Takeda Rabics) that show non-insulin dependent diabetes mellitus (NIDDM) and spontaneously develop diabetic nephropathy and their normal control male Wistar lean rats (Takeda Rabics) that have the same week-age, urine was accumulated for 24 hours and blood was collected from tail vein to determine the urinary albumin excretion, the concentrations of glucose and insulin in the plasma. The urinary albumin excretion was determined with A/G B Test Wako (Wako Pure Chemical Industries); the concentrations of glucose in the plasma were determined with Synchron CX5 Delta (Beckman Coulter). The concentrations of insulin were determined by the RIA method (Shionogi & Co. Ltd.).

35 [0241] The kidneys were collected from five rats of each case and stored at -80°C, and then were crushed to extract total RNA. The primers and fluorescent probe were made on the basis of the mRNA sequence previously reported, and subsequently the amount of each of individual mRNAs was determined using ABI PRISM 7700 (Applied Biosystems) by the real time quantitative RT-PCR method.

40 [0242] The results are shown in [Table 1] and [Table 2]. The Wistar fatty rat showed NIDDM from the age of 13 weeks and developed DN from the age of 22 weeks; as a result, the urinary albumin excretion was increased. It showed an increase in the level of Egr-1 mRNA expression after the age of 22 weeks, and increases in the level of expression of Transforming growth factor- β 1 (TGF- β 1) and fibronectin mRNA at the age of 40 weeks.

[Table 1]

45

Urinary albumin excretion, concentration of glucose in plasma and concentration of insulin in plasma						
	Wistar lean rat			Wistar fatty rat		
weeks age	13	22	40	13	22	40
50 Urinary albumin excretion (mg/day)	5.1	4.0	10.4	6.7	55.7	182.0
Concentration of glucose in plasma (mg/dl)	138.9	137.1	134.3	319.2	402.9	319.4
Concentration of insulin in plasma (μ Units/ml)	123.0	125.6	158.7	1091.9	1019.2	1674.4
(n=5, Mean)						

55

[Table 2]

The mRNA expression levels of Egr-1, TGF- β 1 and fibronectin in the kidney of Wistar fatty rats (Relative values when the expression level in the kidney of Wistar lean rats is equal to one)

Weeks age	13	22	40
Egr-1	1.1	2.2	2.4
TGF- β 1	1.1	1.0	1.7
Fibronectin	1.2	1.0	2.1
(n=5, Mean)			

EXPERIMENTAL EXAMPLE 2

Changes in the early growth response-1 (Egr-1) mRNA expression in the kidney of Zucker fatty rats

[0243] To a male Zucker fatty rat (ZF rat, 18 weeks age, Charles River Japan Inc.) that shows hyperinsulinemia and spontaneously develops a renal damage, Candesartan cilexetil (angiotensin II type 1 receptor antagonist) suspended in 0.5% methylcellulose 100cP was orally administered once per day everyday for 9 weeks. To the control group and the normal control group, i.e., male Zucker lean rats (ZL rat, Charles River Japan Inc.) with the same age, 0.5% methylcellulose 100cP (Vehicle) was administered once per day everyday. Eight weeks after administration, urine was accumulated for 24 hours, and then the urinary albumin excretion was determined using A/G B Test Wako (Wako Pure Chemical Industries). Nine weeks after administration, the kidneys were collected and stored at -80°C, and subsequently the kidneys were crushed to extract the total RNA. The primers and fluorescent probe were prepared on the basis of the mRNA sequence previously reported, and then the amount of each of individual mRNAs was determined using ABI PRISM 7700 (Applied Biosystems) by the real time quantitative RT-PCR method.

[0244] The results are shown in [Table 3] and [Table 4]. In the kidney from the Zucker fatty rat in which the urinary albumin excretion is increased, the amount of Egr-1 mRNA expression is increased and also each mRNA expression of Transforming growth factor- β 1 (TGF- β 1), platelet-derived growth factor-B (PDGF-B), fibronectin and α 1(I) collagen is increased. Furthermore, inhibition of an increase in the urinary albumin excretion by Candesartan cilexetil administration also inhibits the increase in the level of any of the aforementioned mRNA expression.

[Table 3]

Urinary albumin excretion, concentration of glucose in blood and concentration of insulin in blood			
	ZL rat Vehicle	ZF rat Vehicle	ZF rat Candesartan cilexetil
Urinary albumin excretion (mg/day)	48.5	401.5	61.7
(n=8 - 9, Mean)			

[Table 4]

The mRNA expression levels of Egr-1, TGF- β 1, PDGF-B, fibronectin and α 1 (I) collagen in the kidney of Zucker Fatty Rats (Relative values when the expression level in the kidney of the ZL rat is equal to one)

	ZF rat Vehicle	ZF rat Candesartan
Egr-1	2.9	1.3
TGF- β 1	2.1	1.2
PDGF-B	1.5	1.0
Fibronectin	2.1	1.1
α 1 (I) collagen	2.3	1.6
(n=8 - 9, Mean)		

EXPERIMENTAL EXAMPLE 3

Increase in the early growth response-1 (Egr-1) mRNA expression in rat glomerular mesangial cells

[0245] Glomerular mesangial cells (passage 7) isolated and cultivated from a male Sprague-Dawley rat (SD rat,

Japan Crea) of the age of 4 weeks were cultivated in DMEM medium containing 20% fetal calf serum (FCS) for 4 days, and then the cells were cultivated in DMEM containing 0.2% bovine serum albumin for 3 days.

[0246] To the cells after cultivation, FCS (20%) or angiotensin II (All) (10^{-6} M) was added, and then the resulting mixture was reacted at 37°C for 30 minutes. The All type 1 receptor antagonist Candesartan of 10^{-5} M as the final concentration was added to the medium 5 minutes prior to the stimulation of FCS or All. Thirty minutes after FCS or All stimulus, total RNA was extracted. The primers and fluorescent probe were prepared on the basis of the mRNA sequence previously reported, and subsequently the level of Egr-1 mRNA expression was determined using ABI PRISM 7700 (Applied Biosystems) by the real time quantitative RT-PCR method.

[0247] The results are shown in [Table 5] and [Table 6]. The amount of Egr-1 mRNA expression was remarkably increased 30 minutes after FCS stimulus, and was partially inhibited with candesartan. Also, 30 minutes after All stimulus, the amount of Egr-1 mRNA expression was slightly increased, and was mostly suppressed with Candesartan.

[Table 5]

Increase in the Egr-1 mRNA expression by FCS Stimulus and inhibitory effect by Candesartan (Relative values when the expression level before stimulus is equal to one)	
	Egr-1 mRNA expression level
Before stimulus	1.0
30 minutes after FCS stimulus + Vehicle	26.6
30 minutes after FCS stimulus + Candesartan	18.4
(n=3, Mean)	

[Table 6]

Increase in the Egr-1 mRNA expression by All Stimulus and inhibitory effect by Candesartan (Relative values when the expression level before stimulus is equal to one)	
	Egr-1 mRNA expression level
Before stimulus	1.0
30 minutes after All stimulus + Vehicle	2.8
30 minutes after All stimulus + Candesartan	1.3
(n=3, Mean)	

EXPERIMENTAL EXAMPLE 4

Increase in the early growth response-1 (Egr-1) mRNA in the kidney of spontaneously hypercholesterolemic rats

[0248] Using male spontaneously hypercholesterolemic rats (SHC rats, 11 weeks age, Takeda Rabbits), which develop renal damage spontaneously, and normal control male Sprague-Dawley rats (SD rat, Crea Japan Inc.) that have the same week-age, urine was accumulated for 24 hours and blood was collected from tail vein to determine the urinary albumin excretion and the total cholesterol in the plasma. The urinary albumin excretion was determined with A/G B Test Wako (Wako Pure Chemical Industries, Ltd.); Total cholesterol concentrations in the plasma were determined using Synchron CX5 Delta (Beckman Coulter).

[0249] The kidneys were collected at 12 weeks age and stored at -80°C, and then were crushed to extract total RNA. The primers and fluorescent probe were made on the basis of the mRNA sequence previously reported, and subsequently the levels of Egr-1 mRNA expression were determined using ABI PRISM 7700 (Applied Biosystems) by the real time quantitative RT-PCR method.

[0250] The urinary albumin excretion for 12-week-old SHC rats and SD rats were, respectively, 179.2 and 9.2 (mg/day, Mean (n = 5)), and the concentrations of cholesterol in the plasma were, respectively, 92.4 and 43.5 (mg/dl, Mean (n = 5)), with any of the parameters in the SHC rats being high. The amounts of Egr-1 mRNA expression in the kidneys of the SHC rats were increased 3.8 times (Mean (n = 5)) those of Egr-1 mRNA expression in the kidneys of the SD rats.

EXPERIMENTAL EXAMPLE 5

Induction for expression of renal fibrosis-related genes by the early growth response (Egr)-1 overexpression in HEK-293 cells derived from human fetal kidney

[0251] HEK-293 cells (CRL-1573, ATCC, passage 40) derived from a human fetal kidney was cultivated for a day in DMEM medium containing 10% fetal bovine serum, and then a human Egr-1 expression plasmid was transfected into the cell at the concentration of 2 µg/dish using 20 µg/3.5 cm dish of Polyfect (QIAGEN). In addition, as the Egr-1 expression plasmid, a plasmid in which cDNA of the coding region of human Egr-1 was inserted into the pBK-CMV vector (STRATAGENE) was used. Only the pBK-CMV vector used in the Egr-1 plasmid preparation was incorporated into the control cell. 24 Hours after transfection, the cells were harvested to extract protein and total RNA. For the Egr-1 protein expression, after conduct of SDS-PAGE, Western blotting using the Egr-1 specific antibody (Anti-Egr-1 (C-19), SantaCruz) was performed, and then the bands were detected by the chemoluminescence technique (PIERCE). The brightness accumulation value of the band thus detected was calculated by a CS Analyzer 1.00a (ATTO). Also, the levels of mRNA expression of the renal fibrosis-related genes were determined by preparing the primer and fluorescent probe on the basis of the mRNA sequence previously reported and by using ABI PRISM 7700 (Applied Biosystems) by means of the real time quantitative RT-PCR method.

[0252] The results are shown in [Table 7]. The transfection of the Egr-1 expression plasmid increases the Egr-1 protein expression and also the mRNA expression levels of the renal fibrosis-related genes such as tissue factor, fibronectin, and intercellular adhesion molecule (ICAM)-1.

[Table 7]

Increase in the Egr-1 protein expression and increase in the expression of renal fibrosis-related genes by transfection of Egr-1 plasmid (Relative values when the expression level of control is equal to one)	
	Human Egr-1 expression plasmid-transfected cells
Egr-1 protein	1.5
Tissue factor mRNA	1.6
Fibronectin mRNA	1.3
ICAM-1 mRNA	4.9
(n=3 - 6, Mean)	

EXAMPLE 1

Study on the effect of the early growth response-1 (Egr-1) antisense oligodeoxynucleotide (AS-ODN) in rat glomerular mesangial cells

[0253] Glomerular mesangial cells (passage 4-5) isolated and cultivated from a male SD rat with 4 weeks age were cultivated for 3 to 4 days in DMEM medium containing 20% fetal bovine serum to sub-confluence, and the medium was changed to DMEM containing a 0.2% bovine serum albumin and then the resulting material was subjected to serum starvation. Forty-eight hours after initiation of the serum starvation, Egr-1 AS-ODN (SEQ ID NO: 7) or a Control-ODN (the scrambled ODNs that were matched with the AS-ODN in size and the number of bases, both synthesized by BIOGNOSTIK Corp.) with a concentration of 20 µM was added to the medium and the resultant material was allowed to stand in a CO₂ incubator for 24 hours. Thereafter the material was stimulated with a basic fibroblast growth factor (bFGF) (3 ng/ml), and then was reacted at 37°C for 1 to 2 hours. A protein was extracted from the cell one hour after bFGF stimulus, and total RNA was extracted from a cell two hours after bFGF stimulus. The expression of the Egr-1 protein, after conduct of SDS-PAGE, was subjected to Western blotting using the Egr-1 specific antibody (Anti-Egr-1 (C-19), SantaCruz) to detect bands by the chemoluminescence technique (PIERCE). The brightness accumulation value of the band thus detected was calculated by a CS Analyzer 1.00a (ATTO). Also, the mRNA expression level of the tissue factor was determined by making the primer and fluorescent probe on the basis of the mRNA sequence previously reported and by using ABI PRISM 7700 (Applied Biosystems) by means of the quantitative RT-PCR method.

[0254] The results are shown in [Table 8]. The Egr-1 protein expression one hour after bFGF stimulus was increased up to 5.1-fold and this increase was suppressed by Egr-1 AS-ODN treatment. Inhibitory action was not observed at all by Control-ODN treatment. In addition, the tissue factor mRNA was increased up to 2.5-fold, and this increase was almost completely suppressed by Egr-1 AS-ODN treatment. Inhibitory action was not recognized in the Control-ODN treatment group. Furthermore, cytotoxicity by transfection of the Egr-1 AS-ODN was not observed.

[Table 8]

The effects of the Egr-1 AS-ODN transfection on the expression of the Egr-1 protein and the expression of tissue factor mRNA after bFGF stimulus(Relative values when the expression level of control is equal to one)				
Stimulus	Control		bFGF (3 ng/ml)	
Treatment	Vehicle	Vehicle	AS-ODN	Control-ODN
Egr-1 protein	1.0	5.1	2.0	7.0
Tissue factor mRNA	1.0	2.5	1.1	4.6
(n=2 - 3, Mean)				

EXAMPLE 2

15 Quantification of the Egr-1 protein utilizing DNA binding activity

[0255] A system of quantifying the Egr-1 protein with a microplate was set by the combination of synthetic DNA having the Egr-1 binding sequence and the anti-Egr-1 antibody.

20 (1) Construction of plasmids for Egr-1 expression and expression thereof in animal cells

[0256] In order to obtain the human Egr-1 cDNA, a polymerase chain reaction was carried out using as a template cDNA (Clontech Corp.) derived from human fat tissues and synthetic DNA (SEQ ID NOS: 8 and 9) as a primer. The terminal portion of the amplified cDNA was cleaved by the restriction enzymes EcoRI and PstI, and the fragment thus obtained was cloned into the plasmid pcDNA3.1 (+) (Invitrogen Corp.) cleaved by EcoRI and PstI to confirm the base sequence.

[0257] In petri dishes for cultivation (3003; FALCON Corp.) were each planted the cultivated cell HEK293 derived from human with a number of 2×10^6 using as a medium DMEM containing 10% FCS and 100 μ g/ml of kanamycin. On the next day, the gene was introduced into cells using 20 μ g of the aforementioned plasmid for Egr-1 expression and Lipofectamine 2000 (Invitrogen Corp.). After 48 hours, the medium was removed, and the resulting cells were washed with PBS, and then to these were added a 0.5 ml of lysis solution (solution produced by adding to an aqueous solution containing 25 mM Tris-HCl (pH 7.4), 0.4 M NaCl, 100 μ M EDTA, 1 mM DTT and 1% TritonX-100, 1/100 volume of Protease inhibitor cocktail (SIGMA Corp. P8340)) to lyse the cells, which were collected in a sample tube. After the tube was allowed to stand on ice for 5 minutes, the cells were agitated for 10 seconds with a Vortex mixer and centrifuged at 12000xg at 4°C for 5 minutes to obtain the supernatant. This was used as the standard sample. Similarly, the vector, pcDNA3.1(+) was also introduced. The cell lysate was used as the control.

(2) Detection of Egr-1

[0258] The Egr-1 binding sequence-containing synthetic DNA (SEQ ID NO: 10) in which the 5' terminus was labeled with biotin, was made to form the double-strands with the synthetic DNA having the complementary strand (the complementary strand was not labeled with biotin). Also, the synthetic DNA (SEQ ID NO: 11) into which a base substituent hindering the binding of Egr-1 was introduced was also made to form the double-stranded chain, which was used as the control. These were diluted to a final concentration of 50 nM with Block Ace (containing 1mM EDTA) (product of Snow Brand Milk Products Co., Ltd., purchased from Dainippon Pharmaceutical Co. Ltd.) diluted 4-fold with PBS, and 100 μ l aliquots each was added to 96-well plates (IWAKI) immobilized with streptoadipin. After the resulting plate was allowed to stand at room temperature for 30 minutes, the solution was removed by suction, to the resultant plate was added 300 μ l of Block Ace (containing 1mM EDTA) diluted 4-fold with PBS and the material thus obtained was allowed to stand at room temperature for 3 hours. After removal of the solution, the resultant plate was washed 3 times with 300 μ l of PBS. To each well of the plate thus obtained was added 100 μ l of a standard sample diluted 50-fold with a measuring buffer [50 mM Tris-HCl (pH 7.4), 100 mM NaCl, 10% Block Ace, 200 μ M ZnSO₄, 250 μ M MDTT, 10 μ g/ml poly dI-dC (Amersham Corp.), 0.05% Triton X-100] or 100 μ l of the control sample (prepared in (1) described above). After the resultant plate was allowed to stand at room temperature for 40 minutes, it was washed 3 times with a 300 μ l of a washing solution (2 mM imidazole-buffered saline, 0.02% Tween 20, 200 μ M ZnSO₄). To each well of the plate thus obtained was added 100 μ l of anti-Egr-1 antigen (rabbit, polyclonal antibody, SANTA CRUZ Corp., sc-189) that was diluted 500-fold with a measuring buffer not containing poly dI-dC, and the resulting plate was allowed to stand at 4°C for 5 hours. The plate thus obtained was washed 3 times with the 300 μ l washing solution, and to each well of the plate was added 100 μ l of anti rabbit IgG antigen (HRP labeling, Cell Signaling Corp.) that was diluted 2000-fold with

a measuring buffer not containing poly dl-dC, and thereafter the resultant plate was allowed to stand at 4°C overnight. The plate thus obtained was washed 6 times with the 300 µl washing water, followed by staining the well material by adding 100 µl of a TMB solution (DAKO Corp.) and stopping the reactions by adding 100 µl of 2N sulfuric acid. The products in the well were determined for absorbance at 450 nm on an photometer (TECAN Corp., Spectrarainbow).

5 [0259] The absorbance when a dissolution solution of cells into which Egr-1 cDNA was introduced was used by means of a plate on which synthetic DNA of a sequence capable of binding Egr-1 was 0.751. The absorbance when the same sample was determined using a plate on which DNA of non-binding sequence was immobilized was 0.016, and the absorbance using a plate without immobilizing DNA was 0.005. The absorbance value when a measurement
10 was carried out using cell lysate into which Egr-1 cDNA was not introduced, with a plate on which DNA of binding sequence was immobilized, was 0.005.

INDUSTRIAL APPLICABILITY

15 [0260] The screening method of the present invention enables screening of a prophylactic and therapeutic product for renal diseases and the like, with excellent effects and no adverse reactions.

SEQUENCE LISTING

<110> Takeda Chemical Industries, Ltd.
 5 <120> Screening Method
 <130> P04-080PCT
 <150> JP 2002-3769
 10 <151> 2002-01-10
 <160> 11
 <170> PatentIn version 3.1
 15 <210> 1
 <211> 123
 <212> PRT
 <213> Homo sapiens
 <220>
 20 <221> MISC_FEATURE
 <223> Partial amino acid sequence of Egr-1 protein which is conserved
 between human, mouse and rat.
 <400> 1
 25 Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn
 1 5 10 15
 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val
 20 25 30
 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Glu Leu Thr Arg His
 35 40 45
 30 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met
 50 55 60
 Arg Asn Phe Ser Arg Ser Asp His Leu Thr Thr His Ile Arg Thr His
 65 70 75 80
 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala
 85 90 95
 35 Arg Ser Asp Glu Arg Lys Arg His Thr Lys Ile His Leu Arg Gln Lys
 100 105 110
 Asp Lys Lys Ala Asp Lys Ser Val Val Ala Ser
 115 120
 <210> 2
 40 <211> 543
 <212> PRT
 <213> Homo sapiens
 <400> 2
 45 Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile
 1 5 10 15
 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr
 20 25 30
 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe
 35 40 45
 50 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser
 50 55 60
 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser
 65 70 75 80
 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro
 85 90 95
 55 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn
 100 105 110
 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu

115 120 125
 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn
 130 135 140
 5 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly
 145 150 155 160
 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ala Pro Ser
 165 170 175
 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys
 180 185 190
 10 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr
 195 200 205
 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala
 210 215 220
 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr
 225 230 235 240
 15 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu
 245 250 255
 Phe Pro Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys
 260 265 270
 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro
 275 280 285
 20 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu
 290 295 300
 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg
 305 310 315 320
 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg
 325 330 335
 25 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser
 340 345 350
 Asp Glu Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe
 355 360 365
 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr
 370 375 380
 30 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile
 385 390 395 400
 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Thr Lys
 405 410 415
 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala
 420 425 430
 35 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr
 435 440 445
 Ser Tyr Pro Ser Pro Val Thr Ser Tyr Pro Ser Pro Ala Thr Thr
 450 455 460
 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser
 465 470 475 480
 40 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala
 485 490 495
 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser
 500 505 510
 45 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu
 515 520 525
 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys
 530 535 540

<210> 3
 <211> 1629
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)..(1629)
 <223>

	<400>	3		
	atg gcc gcg gcc aag gcc gag atg cag ctg atg tcc ccg ctg cag atc			48
	Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile			
5	1 5 10 15			
	tct gac ccg ttc gga tcc ttt cct cac tcg ccc acc atg gac aac tac			96
	Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr			
	20 25 30			
	cct aag ctg gag gag atg atg ctg ctg agc aac ggg gct ccc cag ttc			144
	Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe			
10	35 40 45			
	ctc gcc gcc gcc ggg gcc cca gag ggc agc ggc agc aac agc agc agc			192
	Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser			
	50 55 60			
	agc agc agc ggg ggc ggt gga ggc ggc ggg ggc ggc agc aac agc agc			240
	Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser			
15	65 70 75 80			
	agc agc agc agc acc ttc aac cct cag gcg gac acg ggc gag cag ccc			288
	Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro			
	85 90 95			
	tac gag cac ctg acc gca gag tct ttt cct gac atc tct ctg aac aac			336
	Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn			
20	100 105 110			
	gag aag gtg ctg gtg gag acc agt tac ccc agc caa acc act cga ctg			384
	Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu			
	115 120 125			
	ccc ccc atc acc tat act ggc cgc ttt tcc ctg gag cct gca ccc aac			432
	Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn			
25	130 135 140			
	agt ggc aac acc ttg tgg ccc gag ccc ctc ttc agc ttg gtc agt ggc			480
	Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly			
	145 150 155 160			
	cta gtg agc atg acc aac cca ccg gcc tcc tcg tcc tca gca cca tct			528
	Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser			
30	165 170 175			
	cca qcq qcc tcc tcc qcc tcc gcc tcc cag agc cca ccc ctg agc tgc			576
	Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys			
	180 185 190			
	gca gtg cca tcc aac gac agc agt ccc att tac tca gcg gca ccc acc			624
	Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr			
35	195 200 205			
	ttc ccc acg ccg aac act gac att ttc cct gag cca caa agc cag gcc			672
	Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala			
	210 215 220			
	ttc ccg ggc tcg gca ggg aca gcg ctc cag tac ccg cct cct gcc tac			720
	Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr			
40	225 230 235 240			
	cct gcc gcc aag ggt ggc ttc cag gtt ccc atg atc ccc gac tac ctg			768
	Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu			
	245 250 255			
	ttt cca cag cag cag ggg gat ctg ggc ctg ggc acc cca gac cag aag			816
	Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys			
45	260 265 270			
	ccc ttc cag ggc ctg gag agc cgc acc cag cag cct tcg cta acc cct			864
	Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro			
	275 280 285			
	ctg tct act att aag gcc ttt gcc act cag tcg ggc tcc cag gac ctg			912
	Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu			
50	290 295 300			
	aag gcc ctg aat acc agc tac cag tcc cag ctc atc aaa ccc agc cgc			960
	Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg			
	305 310 315 320			
	atg cgc aag tat ccc aac cgg ccc agc aag acg ccc ccc cac gaa cgc			1008
	Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg			
55	325 330 335			

cct tac gct tgc cca gtg gag tcc tgt gat cgc cgc ttc tcc cgc tcc 1056
 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser
 340 345 350
 gag gag ctc acc cgc cac atc cgc atc cac aca ggc cag aag ccc ttc 1104
 Asp Glu Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe
 355 360 365
 cag tgc cgc atc tgc atg cgc aac ttc agc cgc agc gac cac ctc acc 1152
 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr
 370 375 380
 acc cac atc cgc acc cac aca ggc gaa aag ccc ttc gcc tgc gac atc 1200
 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile
 385 390 395 400
 tgt gga aga aag ttt gcc agg agc gat gaa cgc aag agg cat acc aag 1248
 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Thr Lys
 405 410 415
 atc cac ttg cgg cag aag gac aag aaa gca gac aaa agt gtt gtg gcc 1296
 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala
 420 425 430
 tct tcg gcc acc tcc tct ctc tct tcc tac ccg tcc ccg gtt gct acc 1344
 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr
 435 440 445
 tct tac ccg tcc ccg gtt act acc tct tat cca tcc ccg gcc acc acc 1392
 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr
 450 455 460
 tca tac cca tcc cct gtg ccc acc tcc ttc tcc tct ccc gcc tcc tcg 1440
 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser
 465 470 475 480
 acc tac cca tcc cct gtg cac agt ggc ttc ccc tcc ccg tcg gtg gcc 1488
 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala
 485 490 495
 acc acg tac tcc tct gtt ccc cct gct ttc ccg gcc cag gtc agc agc 1536
 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser
 500 505 510
 ttc cct tcc tca gct gtc acc aac tcc ttc agc gcc tcc aca ggg ctt 1584
 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu
 515 520 525
 tcg gac atg aca gca acc ttt tct ccc agg aca att gaa att tgc 1629
 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys
 530 535 540
 <210> 4
 <211> 1629
 <212> DNA
 <213> Homo sapiens
 ?
 <220>
 <221> CDS
 <222> (1)..(1629)
 <223>
 45 <400> 4
 atg gcc gcg gcc aag gcc gag atg cag ctg atg tcc ccg ctg cag atc 48
 Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile
 1 5 10 15
 tct gac ccg ttc gga tcc ttt cct cac tcg ccc acc atg gac aac tac 96
 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr
 20 25 30
 cct aag ctg gag gag atg atg ctg ctg agc aac ggg gct ccc cag ttc 144
 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe
 35 40 45
 ctc gcc gcc gcc ggg gcc cca gag ggc agc gcc agc aac agc agc agc 192
 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser
 50 55 60
 agc agc agc ggg ggc ggt gga ggc ggc ggg ggc ggc agc aac agc agc 240

	Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser	
	65 70 75 80	
	agc agc agc agc acc ttc aac cct cag gcg gac acg ggc gag cag ccc	288
5	Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro	
	85 90 95	
	tac gag cac ctg acc gca gag tct ttt cct gac atc tct ctg aac aac	336
	Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn	
	100 105 110	
	gag aag gtg ctg gtg gag acc agt tac ccc agc caa acc act cga ctg	384
10	Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu	
	115 120 125	
	ccc ccc atc acc tat act ggc cgc ttt tcc ctg gag cct gca ccc aac	432
	Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn	
	130 135 140	
	agt ggc aac acc ttg tgg ccc gag ccc ctc ttc agc ttg gtc agt ggc	480
15	Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly	
	145 150 155 160	
	cta gtg agc atg acc aac cca ccg gcc tcc tcg tcc tca gca cca tct	528
	Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser	
	165 170 175	
	cca gcg gcc tcc tcc gcc tcc gcc tcc cag agc cca ccc ctg agc tgc	576
20	Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys	
	180 185 190	
	gca gtg cca tcc aac gac agc agt ccc att tac tca gcg gca ccc acc	624
	Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr	
	195 200 205	
	ttc ccc acg ccg aac act gac att ttc cct gag cca caa agc cag gcc	672
25	Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala	
	210 215 220	
	ttc ccg ggc tcg gca ggg aca gcg ctc cag tac ccg cct cct gcc tac	720
	Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr	
	225 230 235 240	
	cct gcc gcc aag ggt ggc ttc cag gtt ccc atg atc ccc gac tac ctg	768
30	Pro Ala Ala Lys Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu	
	245 250 255	
	ttt cca cag cag cag ggg gat ctg ggc ctg ggc acc cca gac cag aag	816
	Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys	
	260 265 270	
	ccc ttc cag ggc ctg gag agc cgc acc cag cag cct tcg cta acc cct	864
35	Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro	
	275 280 285	
	ctg tct act att aag gcc ttt gcc act cag tcg ggc tcc cag gac ctg	912
	Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu	
	290 295 300	
	aag gcc ctc aat acc agc tac cag tcc cag ctc atc aaa ccc agc cgc	960
40	Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg	
	305 310 315 320	
	atg cgc aag tac ccc aac ccg ccc agc aag acg ccc ccc cac gaa cgc	1008
	Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg	
	325 330 335	
	cct tac gct tgc cca gtg gag tcc tgt gat cgc cgc ttc tcc cgc tcc	1056
45	Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser	
	340 345 350	
	gac gag ctc acc cgc cac atc cgc atc cac aca ggc cag aag ccc ttc	1104
	Asp Glu Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe	
	355 360 365	
	cag tgc cgc atc tgc atg cgc aac ttc agc cgc agc gac cac ctc acc	1152
50	Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr	
	370 375 380	
	acc cac atc cgc acc cac aca ggc gaa aag ccc ttc gcc tgc gac atc	1200
	Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile	
	385 390 395 400	
55	tgt gga aga aag ttt gcc agg agc gat gaa cgc aag agg cat acc aag	1248
	Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Thr Lys	

```

      405      410      415
atc cac ttg cgg cag aag gac aag aaa gca gac aaa agt gtt gtg gcc 1296
Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala
      420      425      430
5 tct tcg gcc acc tcc tct ctc tct tcc tac ccg tcc ccg gtt gct acc 1344
Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr
      435      440      445
tct tac ccg tcc ccg gtt act acc tct tat cca tcc ccg gcc acc acc 1392
Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr
      450      455      460
10 tca tac cca tcc cct gtg ccc acc tcc ttc tcc tct ccc ggc tcc tcg 1440
Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser
      465      470      475      480
acc tac cca tcc cct gtg cac agt ggc ttc ccc tcc ccg tcg gtg gcc 1488
Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala
      485      490      495
15 acc acg tac tcc tct gtt ccc cct gct ttc ccg gcc cag gtc agc agc 1536
Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser
      500      505      510
ttc cct tcc tca gct gtc acc aac tcc ttc agc gcc tcc aca ggg ctt 1584
Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu
      515      520      525
20 tcg gac atg aca gca acc ttt tct ccc agg aca att gaa att tgc 1629
Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys
      530      535      540

```

```

25 <210> 5
    <211> 9
    <212> DNA
    <213> Artificial

```

```

    <220>
    <221> misc_feature
30 <223> Oligonucleotide designed to act as decoy for Egr-1.

```

```

<400> 5
gcgtgggcg

```

9

```

35 <210> 6
    <211> 9
    <212> DNA
    <213> Artificial

```

```

    <220>
    <221> misc_feature
9 <223> Oligonucleotide designed to act as decoy for Egr-1.

```

```

<400> 6
gcggggggcg

```

9

```

45 <210> 7
    <211> 20
    <212> DNA
    <213> Artificial

```

```

    <220>
50 <221> misc_feature
    <223> Oligonucleotide designed to act as antisense DNA for Egr-1 mRNA.

```

```

<400> 7
gcgggggtgca ggggcacact

```

20

```

55 <210> 8
    <211> 30

```

<212> DNA
 <213> Artificial

5 <220>
 <221> misc_feature
 <223> Oligonucleotide designed to act as primer for amplifying Egr-1 cDNA.

10 <400> 8
 ccgaattcag tgttccccgc gccccgcatg 30

<210> 9
 <211> 29
 <212> DNA
 <213> Artificial

15 <220>
 <221> misc_feature
 <223> Oligonucleotide designed to act as primer for amplifying Egr-1 cDNA.

20 <400> 9
 ggctcgagaa cctccatctg acctaagag 29

<210> 10
 <211> 26
 <212> DNA
 25 <213> Artificial

<220>
 <221> misc_feature
 <223> Oligonucleotide designed to act as sense strand of double-stranded DNA capable of binding with Egr-1.

30 <400> 10
 tgactcgccc tcgccccgcg gccggg 26

<210> 11
 <211> 26
 <212> DNA
 35 <213> Artificial

<220>
 <221> misc_feature
 <223> Oligonucleotide designed to act as sense strand of double-stranded DNA incapable of binding with Egr-1.

40 <400> 11
 tgactcgccc tcgaccacgc gccggg 26

45

Claims

1. A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof.
2. A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the amino acid sequence represented by SEQ ID NO: 1, which is characterized by using the protein or salts thereof.
3. The screening method according to claim 1, wherein the protein has the amino acid sequence represented by SEQ ID NO: 2.

4. The screening method according to claim 1, wherein the disease is a renal disease.
5. The screening method according to claim 4, wherein the renal disease is an Egr-1 depending renal disease.
- 5 6. The screening method according to claim 4, wherein the renal disease is diabetic nephropathy.
7. The screening method according to claim 1, which is characterized by comparing production of a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 and the case where
10 a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of a test compound.
8. The screening method according to claim 1, which is characterized by comparing an activity of a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of and in the absence of a test compound.
15
9. The screening method according to claim 8, wherein the activity is a binding activity to the polynucleotide, to which the protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 are capable of binding.
20
10. The screening method according to claim 8, wherein the activity is an expression-controlling activity of a gene under the control of transcriptional control by a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
25
11. The screening method according to claim 1, which is characterized by measuring and comparing production of a protein or salts thereof comprising the same or substantially the same amino acid sequences as that represented by SEQ ID NO: 1, and a binding activity to a polynucleotide, to which the protein or salts thereof is capable of binding, using the polynucleotide and an antibody against the protein or salts thereof in the case where a cell is cultivated that has the capability of producing the protein or salts thereof and the case where the cell is cultivated in the presence of a test compound.
30
12. A compound or salts thereof obtained by the screening method according to claim 1.
- 35 13. A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a compound or salts thereof obtained by the screening method according to claim 1.
14. A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using a polynucleotide comprising a base sequence or a partial sequence thereof encoding a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
p
- 45 15. A screening method for a prophylactic and therapeutic substance for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is characterized by using a polynucleotide comprising a base sequence or a partial sequence thereof encoding a protein or salts thereof comprising the amino acid sequence as that represented by SEQ ID NO: 1.
- 50 16. The screening method according to claim 14, wherein the polynucleotide comprises a base sequence or a partial sequence thereof represented by SEQ ID NO: 3 or SEQ ID NO: 4.
17. The screening method according to claim 14, wherein the disease is a renal disease.
- 55 18. The screening method according to claim 17, wherein the renal disease is an Egr-1 depending renal disease.
19. The screening method according to claim 17, wherein the renal disease is diabetic nephropathy.

20. The screening method according to claim 14, which is **characterized by** comparing the level of RNA encoding a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 and the case where a cell is cultivated that has the capability of producing a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1 in the presence of a test compound.
21. A compound or salts thereof obtained by the screening method according to claim 14.
22. A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a compound or salts thereof obtained by the screening method according to claim 14.
23. An antibody against a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
24. A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises the antibody according to claim 23.
25. A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a polynucleotide having a complementary base sequence to the base sequence encoding a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, or its partial sequence.
26. A diagnostic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises the antibody according to claim 23.
27. A diagnostic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which comprises a polynucleotide having the base sequence or its partial sequence encoding a protein comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1.
28. A prophylactic and therapeutic product for diseases associated with a protein or salts thereof comprising the same or substantially the same amino acid sequence as that represented by SEQ ID NO: 1, which is **characterized by** comprising a polynucleotide having a base sequence represented by SEQ ID NO: 5 or SEQ ID NO: 6.
29. The prophylactic and therapeutic product according to claim 28, wherein the disease is a renal disease.
30. The prophylactic and therapeutic product according to claim 29, wherein the renal disease is an Egr-1 depending renal disease.
31. The prophylactic and therapeutic product according to claim 29, wherein the renal disease is diabetic nephropathy.
32. A prophylactic and therapeutic product for diabetic nephropathy comprising a suppressor of Egr-1.
33. The prophylactic and therapeutic product according to claim 32, wherein the suppressor of Egr-1 is a suppressor of renal Egr-1.
34. A method for the prophylaxis and treatment of diabetic nephropathy in a mammal, which is **characterized by** administering a suppressor of Egr-1 to the mammal.
35. The method according to claim 34, wherein the suppressor of Egr-1 is a suppressor of renal Egr-1.
36. Use of a suppressor of Egr-1 for the manufacture of a prophylactic and therapeutic product for diabetic nephropathy.

37. The use according to claim 36, wherein the suppressor of Egr-1 is a suppressor of renal Egr-1.

5

10

15

20

25

30

35

40

45

50

55

This Page Blank (uspto)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/00111

A. CLASSIFICATION OF SUBJECT MATTER

Int.Cl⁷ G01N33/50, 33/15, C07K16/18, A61K45/00, 48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int.Cl⁷ G01N33/50, 33/15, C07K16/18, A61K45/00, 48/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Jitsuyo Shinan Koho 1922-1996 Toroku Jitsuyo Shinan Koho 1994-2003
 Kokai Jitsuyo Shinan Koho 1971-2003 Jitsuyo Shinan Toroku Koho 1996-2003

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/62561 A (GLAXO GROUP LTD.), 09 December, 1999 (09.12.99), & JP 2002-516676 A	14, 15
X	JP 2000-506725 A (Unisearch Ltd.), 06 June, 2000 (06.06.00), & WO 97/32979 A	25
X	US 6008048 A (ISIS PHARMACEUTICALS INC.), 28 December, 1999 (28.12.99), & EP 1135402 A	25
X	BIOCHEMISTRY AND MOLECULAR BIOLOGY INTERNATIONAL, Vol.32, No.1, (1994), pages 39 to 47	23

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search
14 April, 2003 (14.04.03)Date of mailing of the international search report
30 April, 2003 (30.04.03)Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/00111

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 89/09777 A (ARCH DEVELOPMENT CORP.), 19 October, 1989 (19.10.89), & US 5206152 A	1-11, 14-20, 23-33, 35-37
A	WO 94/23030 A (ARCH DEVELOPMENT CORP.), 13 October, 1994 (13.10.94), & US 5206152 A	1-11, 14-20, 23-33, 35-37
A	WO 01/04356 A (GENE LOGIC INC.), 18 January, 2001 (18.01.01), & AU 6088300 A	1-11, 14-20, 23-33, 35-37
A	WO 01/74298 A (BROWN UNIVERSITY RESEARCH FOUNDATION), 11 October, 2001 (11.10.01), & AU 512401 A	1-11, 14-20, 23-33, 35-37

Form PCT/ISA/210 (continuation of second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP03/00111

Box I Observations where certain claims were found unsearchable (Continuation of Item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1.
- ☒
- Claims Nos.: 34

because they relate to subject matter not required to be searched by this Authority, namely:
It pertains to therapeutic methods.

- 2.
- ☒
- Claims Nos.: 12, 13, 21, 22

because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
It is unclear what substances are involved in the scope of the compounds obtained by the screening method and remedies/preventives containing the compounds are also unclear.

- 3.
- ☐
- Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

This Page Blank (uspto)